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A bstract
Ghrelin is a 28-amino acid peptide hormone that was first discovered in 1999 by
Kojima et al. Recently, we have developed molecular imaging agents using ghrelin
analogues that selectively target the growth hormone secretagogue receptor la (GHSRla). This is accomplished by placing the imaging component at either the C-terminus of
the peptide through a pendant lysine side-chain, or through modification of the Ser-3
residue. Receptor binding assays confirmed that fluorescein ghrelin(l-18) (IC50 = 9.5 nM)
and non-radioactive fluorine and gallium containing ghrelin analogues (IC50 = 2.88 - 65
nM) bound to the GHSR-la with high affinity. Fluorescein ghrelin(l-18) demonstrated
high uptake in the human prostate cancer cell lines PC-3 and LNCaP, as well as ex vivo
human prostate cancer tissue. This work supported the development of a radiolabelling
strategy for incorporating gallium-68 and fluorine-18 into modified ghrelin, for use in
PET nuclear imaging.

Keywords: GHSR-la, Ghrelin, Fluorine-18, Gallium-68, Prostate Cancer, Molecular
Imaging
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Introduction
1.1 Introduction to Molecular Imaging
Over the last 25 years, imaging techniques have enabled scientists to better
understand and monitor disease processes'. In the early 1990s a new term, molecular
imaging, became an extension of this thought process by allowing living subjects to be
visualized in a more meaningful way1,2. Molecular imaging can be defined as “the visual
representation, characterization, and quantification of biological processes occurring at
the cellular or sub-cellular levels” (Massoud et al) . Molecular imaging combines the
basic sciences (cellular/molecular biology, chemistry, physics and pharmacology) with
medical imaging to formulate a unique multidisciplinary field. Today, diagnostic imaging
techniques either use contrast enhancing agents or structurally-based anatomical methods
to visualize living subjects. In contrast to classical imaging techniques, molecular
imaging enhances the spacial resolution, sensitivity, and specificity of an imaging agent.
It provides a non-invasive approach in identifying early stages of disease(s), in contrast to
the invasive method of a traditional surgical biopsy.

\

In order to image and identify malignant tumour cells, an imaging probe needs to
be synthetically designed so that it can distinguish between abnormal and healthy tissues.
When introduced to an in vitro or in vivo environment, imaging probes generally consist
of two parts: (1) a biomolecular vehicle component to ensure successful delivery to the
region of interest, and (2) a signal source to create contrast and be externally detected by
the imaging modality of choice (Figure 1.1). Imaging probe design focuses on
incorporating radionuclides or optical dyes as signalling sources. To limit interference

2
with the cellular binding regions a linker may be situated between the signal source and
biomolecular vehicle.

Linker
Biomolecular Vehicle

Signaling Source

Figure 1.1. Schematic diagram of the design of molecular imaging probes.

In the past imaging techniques focused largely on identifying macroscopic
physical, physiological, or metabolic changes within a subject, differentiating between
diseased and normal tissue without the ability to identify specific molecular events.
Molecular imaging is responsible for the shift from non-specific to specific imaging
techniques. Its impact can be shown through our understanding of integrative biology,
earlier detection methods, characterization of disease, and treatment approaches3.
Fluorodeoxyglucose (1SF-FDG) is an example of a clinically approved molecular imaging
probe which incorporates radioactive fluorine {signal source) into D-glucose
{biomolecular vehicle) as a way of diagnosing disease in many tumour models including
lymphoma, non small cell lung cancer, head and neck cancer, and colorectal cancer
(Figure 1.2)4. In primary tumour cells, glucose metabolism is up-regulated by glucose
transporter (GLUT) proteins and the expression of hexokinases. The ability of FDG to
detect tumour cells with high specificity is because of this relationship between tumour
growth and energy production by glucose metabolism (Warburg effect)5. FDG competes
with glucose and is rapidly transported across the tumour cell membrane where
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phosphorylation takes place. In healthy cells, glucose is phosphorylated by hexokinases to
form glucose-6-phosphatases, which then undergoe additional metabolism. Unlike
glucose, FDG-6-phosphate cannot be further catabolized, which causes it to remain in the
intracellular compartment of tumour cells, thus further improving the imaging potential.

a.

OH

Figure 1.2. (a) Maximum intensity projection of whole body PET scan using the
molecular imaging probe l8F-2-Deoxy-D-Gluocose (IXF-FDG)6 (b) Structure of lxF-FDG.

Modalities utilized in molecular imaging include: positron emission tomography
(PET), single photon emission computed tomography (SPECT), optical fluorescence
imaging, magnetic resonance imaging (MRI), computed tomography (CT), and
ultrasound imaging. While each imaging modality is unique with its own strengths and
limitations, the principal goals remain the same. The goal of molecular imaging is to: (a)
develop a non-invasive technique to assist in clinical diagnosis by providing anatomical
and macrofunctional images of high specificity and sensitivity and (b) improve earlier
diagnosis of disease, leading to higher survival rates.
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1.2 Designing Peptide Based Imaging Probes
The field of molecular imaging has developed several efforts to ensure earlier and
more accurate diagnosis of disease. Initial efforts in developing novel probes utilized the
placement of a radioisotope incorporated within a small molecule or macromolecule7. For
example, the development of antibodies 25 years ago became a popular theme in cancer
imaging. These antibodies acted as biological agents in target delivery for in vivo studies.
Antibodies provided specific information regarding anatomic location of a particular
disease, tissue of origin, and biologic potential7. Although this was a simple principle it
became apparent this method of imaging would be more difficult in translating to the
clinical setting. Antibodies are limited because of their excessive size (150 kDa), lack of
clearance from the body and poor diffusion and permeability properties8,9.
In order for an imaging probe to be successfully implemented into a clinical
setting, it should provide a sufficient target to background ratio to maximize the signal-tonoise contrast in the image. An ideal imaging candidate should bind with high affinity,
show specific uptake and retention time, have high stability and above all be safe for
human use8. Peptides represent a viable class of imaging probes that can fulfill the abovementioned criteria10. These molecules consist of several amino acid sequences, linked
together through peptide bonds. They are smaller than proteins, as they do not form welldefined three dimensional tertiary structures10. Generally, peptides play a limited role
within their biological environments by targeting specific receptors within the brain,
gastrointestinal tract, endocrine, vascular or lymphoid systems. Their functions are
facilitated by high affinity, specific receptors, many of which belong to the G- proteincoupled

family of receptors. These peptide receptors have demonstrated an

overexpression in multiple cancer models, even though they play a physiological role
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within the human body8'11,12’13. This overexpression is why peptide receptors have
become popular and unique in diagnostic imaging applications (Figure 1.3).

Figure 1.3. Principle behind targeting cancer-specific receptors. Signalling source would
create a signal to detect the peptide binding to its overexpressed receptor.

Peptides offer several advantages over small molecules and macromolecules when
being used as a biomolecular vehicle. Bioactive peptides and peptide-based hormones
have a relatively low molecular weight, consisting of less then 50 amino acids. Lower
molecular weight peptides have improved biodistribution because of their excellent tissue
diffusion, specific target accessibility and rapid clearance from the blood9. While peptides
play a limited role within their physiological environment they have limited
immunogenicity as compared to other macromolecules8. Peptides can be readily
synthesized by solid phase peptide synthesis (SPPS), and further manipulated to
incorporate a radioisotope or optical dye14.
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There are also some disadvantages associated with the use of peptide-based
imaging probes. Peptides are limited to imaging tumours present within the peripheral
organs. Less then 0.1% of the peptide will end up circulating within the brain, and
consequently they will usually not cross a healthy blood brain barrier (BBB). This
however could be an advantage, since the brain expresses a high density of peptide
receptors13. Usually peptides have short-lived biological half-lives and consequently are
rapidly degraded by peptidases. As a result they are excreted through renal or
hepatobiliary circulation.
There is the possibility of engineering peptides to improve their overall metabolic
stability, thus increasing the short-lived half-life. Generally, substitution of L-amino acids
with D-amino acids or unnatural amino acids shows an increase in stability. Alternative
methods in improving the peptides stability in vivo can occur through side chain
modification, adding in hydrophilic or hydrophobic substituents, peptide cyclization, and
acetylation or amidation of the peptide backbone16. Due to the small size of peptides,
incorporating a signalling source such as a fluorescent dye or radionuclide, can disturb the
binding affinity of the imaging probe towards the desired receptor target9.
Four different strategies exist when incorporating a radioisotope as the signalling
source to form a peptide-based imaging agent. The first strategy incorporates the
radioisotope directly through a pendent amino acid side chain in one step (Figure 1.4.a).
This method significantly shortens the reaction time, requires low amounts of precursor
and provides reasonable yields17. In a similar approach, a chelate can be incorporated
through a pendent side chain to covalently bind the radioactive element (Figure 1.4.b) .
The location and size of the chelate is critical for preserving the peptides binding affinity
to the targeted receptor. In a different approach, a prosthetic group can be readily
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radiolabelled prior to being added into the backbone of the peptide (Figure 1.4.c).
Methods for incorporating the radioisotope to form the prosthetic group, adding the group
into the peptide and purification techniques along the way, need to be considered to
ensure no loss in radioactivity. The last approach is an integrated design where the
radioactive element is incorporated directly into the structure of the peptide (Figure
1.4.d). The following chapters will discuss the use of chelators and prosthetic groups for
incorporating radioactive elements.

Figure 1.4. Various methods for incorporating radioisotopes for PET nuclear imaging: (a)
Direct labeling pendent design (b) Pendent chelate design (c) Prosthetic group design (d)
Integrated design.

1.3 Fmoc Solid Phase Peptide Synthesis
Merrifield first reported the synthesis of linear peptides on a solid support in
196319. Prior to solid-phase peptide synthesis (SPPS), peptides were synthesized by
classical solution phase techniques20. Solution-phase peptide synthesis is a timeconsuming and arduous task requiring purification after each synthetic step. The intent of
SPPS was to simplify the vigorous task of synthesizing a polypeptide by: creating an
easier method to separate reagents from products, increasing the purity of the peptide by
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having soluble byproducts, removing solvents in a timely efficient process by filtration
and allowing excess reagents to drive reactions to completion. Since Merrifield’s
discovery, SPPS has developed into the most commonly used method for preparing
peptides. Currently, SPPS uses a polystyrene based solid support (resin) with particle
diameters in the range of 20-50 pm . Various cleavable linkers are utilized to attach the
amino acid residues to the solid support, allowing for the release of the final linear
peptide sequence (Figure 1.5) .

Trityl

Merrifield

(ps)^vw^

^ — CH20 - < Q > — CH2OH

Wang

Figure 1,5. Structures of commonly used linkers in SPPS.

Fmoc SPPS is a technique where amino acid residues are added one by one to the
insoluble solid support, in a C to N-terminal methodology. A base-labile Fmoc group
protects the a-amine while an acid-labile group protects the amino acid side chain
functionality. The synthesis starts off by deprotecting the organic linker attached to the
polystyrene resin. The first amino acid is attached to the free amine on the organic linker
by the free carboxylic acid (Scheme 1.1). This occurs in situ where the acid forms an
activated

ester

by

reaction

with

a

coupling

reagent

such

as,

3-

9
[bis(dimethylamino)methyliumyl]-3//-benzotriazol-l-oxide

hexafluorophosphate

(HBTU)14. Afterwards, the Fmoc protecting the a-amine (on the N-terminus) is removed
under basic condition using 20% piperidine in dimethylformamide (DMF). This in turn
produces the free amine, which can undergo a subsequent reaction with the C-terminus of
another free carboxylic acid using standard coupling conditions. The cycle of removing
the Fmoc protecting group on the amino acid linked to the insoluble support, followed by
the addition of another amino acid is repeated until the anticipated sequence is made.
After no further modifications are needed, the acid-labile protecting groups and resin are
cleaved by treating the peptide with a high concentration of trifluoroacetic acid (TFA)
and scavengers such as triisopropylsilane (TIS) and water (Scheme 1.1).
HBTU, DIPEA, DMF

(

')
Peptide

Scheme 1.1. General peptide synthesis using SPPS.
When further modifications to individual side chains are needed or to that of the
resin, an additional orthogonal protecting group strategy is required. This allows for the
selective removal of one protecting group in the presence of others having the same
functionality. This can be done through the use of unique resins or protecting groups that
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tolerate each other’s deprotection strategies. There are a number of different methods that
allow for the selective removal of protecting groups and resins. For example, hyper-acid
sensitive and photo-labile resins are able to give a non-conventional C-terminus upon
being cleaved. Other conventional methods include using weakly acidic protecting groups
and palladium catalyzed protecting groups for further modification to the peptide.
Monitoring the reaction progress in SPPS is a difficult task and causes a degree of
uncertainty during each reaction step. This error is a result of the peptide being linked to
an insoluble solid support that cannot be analyzed using standard chromatographic
techniques. As a result, a small portion of the resin is sacrificed in order to evaluate the
reaction progress. For example, the Kaiser test is a qualitative test that can detect the
presence or absence of a primary amine group, and can confirm the completeness of a
coupling step . In other cases, a micro-cleave sacrifices a small portion of peptide and
cleaves it from the solid support for additional standard chemistry assessments. These
assessments include mass spectroscopy (MS), high-performance liquid chromatography
(HPLC), and nuclear magnetic resonance spectroscopy (NMR). Even though there are
limitations when analyzing the reaction progress in SPPS, it is still the most effective
method in synthesizing peptides. In comparison to solution phase techniques, it uses less
time, produces higher yields, and can be performed by automated synthesis.

1.4 Positron Emission Tomography
Positron emission tomography (PET) is a sensitive modality used to create threedimensional images based on the decay of positron emitting radioisotopes. PET images
provide information about pathophysiological, physiological, and metabolic processes in
comparison to imaging techniques that only display structure, such as CT and MRI
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imaging. However, this technique has been shown to be expensive, uses ionizing
radiation and has limited spacial resolution. Radioisotopes such as IXF, n C, l3N, and l50
can all be produced via a cyclotron. When attached to a biomolecular vehicle and injected
intravenously into a patient, the positron containing agent decays based on its’ half-life.
In the case of fluorine-18, the radionuclide emits a positron, which upon traveling a short
distance, collides with an electron (Figure 1.6). This annihilation results in the emission
of two gamma ray photons of 511 keV at a coincidence angle of 180 degrees. The image
acquisition is based on the detection of a series of 180 degree coincidence gamma rays.
The scintillation detectors are then able to convert the signal into three-dimensional
images with computer software creating the PET image . In addition to PET’s increased
sensitivity and accuracy, it is also available in tandem with other imaging modalities such
as CT or MRI.

1.5 Radioisotopes used in PET Nuclear Imaging
Fluorine-18 has a short half-life of 110 minutes, high-bonding energy with carbon
(481 kJ/mol in CH3-F), small atomic size (0.5 A), and high electronegativity (3.98)24,25.
“Physiological radionuclides” n C, 13N and 150 are preferred for labeling organic
compounds, but due to their short half-lives of 20.4, 10.0, and 2.0 minutes respectively,
these isotopes are limited in designing peptide-based probes labeled with a tracer . F
has an acceptable half-life leaving enough time for both chemical synthesis as well as
imaging experiments, with moderate levels of radiation dose to the patient. Its use is
valuable for PET imaging with 97% of the isotope decaying through positron emission .
Incorporating fluorine into an imaging probe has shown to affect the probe activity and
stability. Its chemical and nuclear properties have been refereed to as the “fluorine effect”
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because depending on the biological system, fluorine can have a positive or negative
effect27. Fluorine can also change the lipophilicity of a peptide, which in turn could
increase or decrease binding affinity to receptors. Although fluorine is closely related to
hydrogen in size, when replacing hydrogen with fluorine it affects the peptide’s
electrostatic interactions as well as electron densities .

( e)
Figure 1.6. The interaction of a positron (E ) emitted from a radioactive source ( FFDG) with an electron (E ). This annihilation event produces two gamma rays at 180
degrees apart. Both gamma rays are detected by scintillation detectors in a PET
instrument, and rendered to display an image.

IXF is generally produced from a cyclotron or linear particle accelerator where
proton irradiation of an lxO enriched water target gives the radioisotope. This method of
production generates high specific activity of IXF (1710 Ci/micromol); however after
irradiation, the radionuclide has to be isolated in order to become reactive . Generally the
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water is removed by the addition of an organic solvent, while heating under and inert
atmosphere. Potassium carbonate is added to act as the cation source followed by the
addition of kryptofix 222, which complexes to the potassium to enhance the
nucleophilicity of fluoride . F decays to O with a maximum decay energy of 635 keV,
followed by gamma emission upon positron electron annihilation (Scheme 1.2)29’30.
Throughout the literature there have been many methods reported for the production of
l8F-labelled compounds, such as the lsF-electrophilic method“9, but for our synthesis we
will be using the most commonly employed method, nucleophilic fluoride addition .

18f _____^

Op --------►
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+

(635 keV, t 1/2- 110 minutes)

2y (511 keV, 180°, detected by PET camera)

Scheme 1.2. Fluorine-18 decay

An alternative method for labeling biomolecules with a PET radionuclide is
through the use of radionuclide generators. When designing generator systems, the
radiation source must be accompanied by a parent source, which has different chemical
properties, allowing for optimal separation. A long-lived parent isotope source gives the
system an adequate lifetime for the synthesis of many tagged biomolecules. Although
gallium generators have been well understood since the 1970’s, their clinical application
has not raised interest in the scientific community until a short time ago . Within the Ge68/ Ga-68 system, the long-lived source, Ge-68, is produced from the (p, 2n) reaction of
Ga-69 (Scheme 1.3)33. This long-lived isotope decays with a half-life of 270 days to
produce Ga-68 via 100% electron capture. As a result of its slower decay, these
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generators can last up to two years . Ga-68 can be eluted off the generator using various
chromatographic techniques and integrated into peptides by using a chelator model.

Ga

has a physical half-life of 68 minutes and decays 89% through positron emission at 1.92
MeV32.
69Ga

--------- ►
(p, 2n)

68Ge

68Ga

-------------- ►

-------------- ► 68Ga
100% e decay

68zn

+

°p

(1899 keV, tv 2 - 68 minutes)

11 % e decay
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°p + °e

--------- 2y (511 keV, 180°, detected by PET camera)

Scheme 1.3. Production of Germanium-68 and Gallium-68.

1.6 Fluorescence Microscopy
Fluorescent microscopy is an emerging method used to detect different types of
diseases. Both in vitro and in vivo fluorescence imaging uses low-light cameras and
appropriate fdters to quantify the emission of light present within a sample34. The samples
that are used for imaging are whole-body animals (in vivo) or cells cultured in dishes (in
vitro). Collectively, these imaging agents are more sensitive, safe, have longer shelf-lives
and are easier to synthesize in comparison to radiopharmaceutical imaging agents. Yet,
there are two reasons why it is technically challenging to develop a fluorescent probe for
in vivo imaging. First, the penetration depth of a fluorescent probe is in the range of a few
centimeters35. Secondly, tissues present within animals are able to absorb and scatter
photons, which generates autofluorescence. This commonly leads to lower signal
intensities

and. problems with quantifying fluorescence . In addition to the

autofluorescence revealed throughout normal tissue, the major decrease in signal to
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background ratio (SBR) results from other photon absorbers such as water, lipids,
oxyhemoglobin, and deoxyhemoglobin36.
When the fluorophore (signal source) absorbs light energy (photons), alterations
in the molecules vibrational, electronic and rotational states occur. Sometimes the
absorbed energy (photon) is able to move an electron from its ground state (lowest energy
level) to a higher energy orbital (excited state) (Figure 1.7.A). Eventually, vibrational
relaxation causes the electron to move to a lower energy state (Figure 1.7.B), which is
then followed by the emission of a photon of energy causing the electron to return to its
ground state (Figure 1.7.C) .
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Figure 1.7. Fluorescence process: (A) Excitation, (B) Vibrational Relaxation, (C)
Emission.

Although there are disadvantages in developing fluorescent imaging probes for in
vivo use, cell-based fluorescence imaging is a widely accepted method. It is currently
used

for high-throughput screening of compounds

for target validation

and

confirmation38. There are a number of different compounds that absorb in the visible
region of the spectrum and as a result can be used to visualize and validate binding to
potential molecular targets (Figure 1.8). Two types of fluorescent imaging probes exist:
(a) non-targeting imaging probes, and (b) targeting probes. Targeting probes can be
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divided into activatable or active agents. In this thesis, active targeting probes will be
described to image the overexpression of receptors present within tumour cell models.
Generally, compounds that exhibit this rapid transition from excited to relaxed states,
display conjugated double bonds, aromatic motifs with pi bonds that can distribute
valence electrons over wide areas. The more conjugated double bonds a fluorophore’s
structure contains, the lower the excited energy requirement, and the longer wavelengths
the excitation light can be. This results in the emitted light being shifted in the same
direction.

S = C= N

A

B

C

\
Figure 1.8. Commonly used fluorophores: (a) F1TC, A-ex ~ 494 nm, Aem ~ 521 nm (b)
Texas Red, Aex~ 589 nm, Aem ~ 615 nm (c) Cy-5.5, Aex~ 494 nm, A ~ 5 2 1 nm.
e m

1.7 Scope of Thesis
In this thesis, the concept of molecular imaging is used in parallel with the design
of novel peptide based imaging probes that target cell-surface receptors. These receptors
have a common feature, as they are overexpressed in abnormal cells and tissues. Each
chapter will focus on the design, synthesis and application of peptide-based imaging
probes. Additionally, each chapter represents a new approach to imaging disease whether
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by incorporating fluorescent probes, gallium-68 or designing small prosthetic groups for
fluorine-18 chemistry.
The second chapter of this thesis introduces the growth hormone secretagogue
receptor (GHSR-la) and its attractiveness as an imaging target. Ghrelin is a 28 amino
acid peptide hormone and is the endogenous ligand for the GHSR-la. Evidence from the
literature suggests the GHSR is overexpressed in a number of tumour models and
diseases. As an initial study, the objective was to design a novel fluorescent imaging
probe using ghrelin, to target the GHSR. The reported design and synthesis of the
imaging agent is highlighted within this chapter. The underlying goal was to validate the
uptake and internalization of modified ghrelin in vitro. Additionally, the author has
incorporated concepts and images from recently accepted publications, highlighting two
separate studies using this probe. This novel idea of developing an imaging probe
targeting the GHSR for cancer detection has only been proposed by our group.
Furthermore, this is the first example of an imaging probe able to differentiate certain
tissues present within ex vivo human prostate tissue. This project was in collaboration
with Dr. Savita Dhanvantari and Dr. John Lewis, both assistant professors in Medical
Biophysics from the University of Western Ontario.
The long-term goal of this project was to develop a radioactive imaging probe for
PET nuclear imaging. Chapter’s three and four look at two different approaches in
designing radioactive peptide-based imaging probes using either gallium-68 (chapter
three) or fluorine-18 (chapter four). Before developing radiolabeling strategies, both
chapters report the design and synthesis of non-radioactive analogs. The binding affinities
of these analogs were evaluated in a biological assay.
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Chapter three of this thesis discusses the design and synthesis of incorporating a
metal chelate into the peptide backbone of ghrelin. This chapter also reports the first
radiolabelled ghrelin analogue for use in molecular imaging. The method of incorporating
radioactive gallium will be discussed in great detail along with future objectives for this
probe.
Chapter four of this thesis discusses methods for incorporating fluorine-18 into a
peptide. Previously, we have published a paper discussing non-radioactive fluorine
TO
bearing ghrelin analogs for imaging the GHSR . The site of fluorination was within
ghrelin’s unique lipophilic octanoylated side chain. The objective of this study was
initially to improve the binding affinities of the fluorine labelled analogs. This was
accomplished by designing second-generation fluorine bearing ghrelin analogs. Because
of the improved binding affinities towards the GHSR a prosthetic group strategy for
incorporating fluorine-18 is discussed. A number of attempts and synthetic routes are
shown for the synthesis of three novel prosthetic groups. One of the prosthetic groups was
radiolabelled with fluorine-18, and following this initial design and, synthesis attempts
were taken to form a fluorine-18 labelled ghrelin analogue.
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C hapter Two: The Design, Synthesis, and A pplication o f a Fluorescein
Labeled G hrelin A nalogue
2.1 Methods in Diagnosing Early Stage Prostate Cancer
Prostate cancer (PCa) is the leading malignancy in North American men. In 2010,
it was estimated that 217,730 new cases developed and 32,050 deaths resulted from PCa
in the United States40. In the last 20 years there has been great progress in our
understanding of how to diagnose PCa effectively41. Currently, the standard method used
to diagnose PCa is the analysis of a patient’s prostate specific antigen (PSA) level42.
Generally, healthy individuals have a PSA level below 4.0 nanograms per millilitre of
blood (ng/mL)42. However, in one study 15.2% of patients living with PCa reported a
PSA level below that of the healthy individual43. In addition to these results, 2.3% of the
overall population had confirmed high-grade PCa with PSA values in the healthy range43.
In another study, 65-75% of individuals who had PSA levels elevated above 4 ng/mL did
not have PCa44. The rather large discrepancies observed in these studies display the
inaccuracy associated with the PSA test and its inability to accurately differentiate
between normal prostate and cancerous tissues. This problem in correctly diagnosing
patients has lead to numerous instances of false positives and negatives45'46.
Current imaging techniques used to detect early and advanced stages of PCa focus
on the visualization and biophysical characterization of prostate carcinomas. For example,
morphological T2 weighted MRI shows the gross anatomy of the prostate gland with high
resolution and can serve as a method to help detect abnormal peripheral tissue (Figure
2.1.a)47. Trans-rectal ultrasound (TrUS) uses high frequency sound waves to detect
changes within the prostate gland, distinguishing normal tissue from abnormal masses
and tumours (Figure 2.1.b)47. Another technique utilized in detecting PCa is that of a

20

•
•
•
•
18
radioisotope for PET nuclear imaging. With the exception of F-FDG, the use of PETradioisotopes within the clinical setting for diagnosing prostate disease has been limited47.
I8F-FDG displays low accumulation in primary prostate cancer cells and is unable to
detect local reoccurrence in patients who have undergone radical prostatectomy48'49.
Although this agent has shown its ability in detecting later stages of PCa (Figure 2.1.c),
often times when using it to image earlier stages, you observe surrounding interference
and overlap in adjacent organs47.

A

B

C

Figure 2.1. (a) T2 weighted MRI of advanced PCa (red arrow) on the periphery of the
prostate gland, (b) Trans-rectal ultrasound of advanced PCa (red arrow), (c) l8F-FDG
PET-CT overlay image showing advanced prostate cancer (red arrow) and surrounding
bladder uptake (yellow arrow) (Fig c)47.

In a recent example the level of F-FDG accumulation within the prostate was
shown to overlap between normal prostate tissue, benign prostatic hyperplasia (BPH),
prostatsis and prostate cancer tissue50 51. This study demonstrated the difficulty in
designing and optimizing imaging probes to differentiate between early staged PCa and
benign prostate hyperplasia (BPH) (Figure 2.2)51. The level of FDG accumulates in both
tissues, making it difficult to distinguish between malignant and benign conditions. In
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addition to the overlap observed in Figure 2.2, both patients had similar PSA levels,
which confirmed the inaccuracy of diagnosing early PCa using an alternative approach.
From this, it has become clear that balancing between early diagnosis and the
potential for overtreatment of prostate cancer has resulted in a clinically relevant
problem52'53. Non-invasive molecular imaging agents targeting cancer-specific receptors,
may offer new insight into solving this dilemma, and could lead to improvements in
distinguishing between aggressive and indolent disease.

CT Scan

PET Scan

Figure 2.2. Top figure represents a patient with early stage PCa. Bottom figure represents
a patient with BPH. In both figures, Red arrows show the anatomic location of the tumour
(CT scan) and accumulation of l8F-FDG (PET scan). Each patient’s condition was
confirmed by post-surgical biopsies51.

2.2 Introduction to Imaging G-Protein Coupled Receptors
Cell-surface G-protein coupled receptors (GPCRs) are well-known targeting
entities that are responsible for modulating almost all physiological processes54. GPCRs
are considered the most diverse class of protein families within the human genome. Of
the 35,000 human genes isolated from the human genome, approximately 720 encode for
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GPCRs and 400 of these are expected to be potential drug targets55,56. Their popularity
has risen over the past decade in behaving as in vivo targets because of their location
lying largely within the plasma membrane of cells. This location has proven a crucial role
in target accessibility, making GPCRs readily available to pharmaceutical agents. Yet,
there has been limited interest in investigating this broad family of receptors for tumour
imaging, even though targeting GPCRs statistically accounts for half of our current
marketed drugs57.
GPCRs can be divided into three major classes (A-C) and three smaller classes
(D-F). These classes are divided based on 20% sequence homology within the receptor
domains58. Structurally, GPCRs as a superfamily share a common regional composition
within their membranes. These receptors are characterized by their seven trans-membrane
(7-TM) alpha helical domain, containing an extracellular N-terminus and cytoplasmic Cterminus.

Figure 2.3. Growth hormone secretagogue receptor indicating the seven trans-membrane
domain.59
2.3 Imaging the Growth Hormone Secretagogue Receptor-la (GHSR-la)
In 1996, Smith et al identified a sub-class of the GPCR family termed the growth
hormone secretagogue receptor (GHSR)59. As is typical, this receptor contains the 7-TM
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characteristic domain with alternating intracellular and extracellular loops (Figure 2.3)59.
The GHSR consists of a 366 amino acid sequence and is involved in the regulation of
growth hormone (GH) secretion60. GHSRs have been further subdivided into receptors
containing an Asp-Arg-Tyr motif on the intracellular portion of loop III (GHSR-1),
secretin family receptors (GHSR-2), and glutamate receptors (GHSR-3). In healthy
individuals, the GHSR-1 has shown to be expressed within endocrine and reproductive
organs, various regions of the brain (hypothalamus, and pituitary gland), bone marrow
and the pancreas60’61'62,63. More importantly, a differential expression of the GHSR is
observed in normal human tissue versus that of various types of tumours including breast
carcinomas, prostate cancer cells, ovarian tumours, testicular tumours, pancreatic
endocrine tumour, and intestinal carcinoids11’12’13,64'65’66’67. This evidence points towards
the ability to use the GHSR as a cancer-specific target for molecular imaging.
In 1999, Kojima et al. reported the purification and identification of the first
/TO

endogenous ligand specific to the GHSR . Ghrelin, a 28 amino acid orexigenic peptide
hormone was first isolated from rat stomach extract, and later determined to be expressed
/TO

#

m

#

throughout the human body (Figure 2.4) . This unique peptide originates from a posttranslational cleavage product of preproghrelin and contains a unique hydrophobic moiety
off of residue 3 (Ser3) 69. The hydroxyl group of the Ser3 residue is octanoylated in the
cell’s cytosome by the enzyme GOAT (ghrelin O-acyl transferase) ’ . Des-octanoylated
(ghrelin with the absence of Ser3 side chain) ghrelin does exist in excess throughout the
body, which is regulated by esterase enzymes via ester hydroylsis69.
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Figure 2.4. Structure of Human Ghrelin.

Ghrelin binds to the growth hormone secretagogue receptor-1 (GHSR-1) with
high affinity and selectivity to form an internalized GHSR-ghrelin complex . Two
transcripts within the GHSR-1 complex have been identified; GHSR-1 a is the
biologically active form of the receptor which ghrelin is able bind to, while GHSR-lb is
truncated version lacking domains 6 and 7 . The goal of this project was to synthesize
molecular imaging probes containing a ghrelin peptide sequence to target tissues which
show a high GHSR-1 a expression. Our objective was to delineate cancerous tissues
present within the prostate from that of benign tissues using a modified ghrelin analogue.
Numerous half-maximal effective concentration (EC50) and half-maximal
inhibitory concentration (IC50) values have been reported throughout the literature
pertaining to ghrelin’s binding affinity to the GHSR-1 a73,74’75’76. In one study, alanine
scans, where an alanine amino acid was substituted in place of each amino acid in the
peptide sequence, were performed on truncated versions of ghrelin . In ghrelin(l-14), no
significant change in binding affinity was observed when substituting the majority of the
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Figure 2.5. Origins of human ghrelin. 69

amino acids with alanine. However, when replacing the octanoylated Ser3, and Phe4
residues a significant decrease in binding affinity was observed (Table 2.1). Modifying
position eight with either tyrosine or alanine leads to an increased receptor recognition
and activation to ghrelin fragments73’75. These results demonstrate that several residues in
ghrelin’s sequence could be modified while having little to no loss in the peptides binding
affinity.
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Table 2.1. Alanine scans on truncated human ghrelin. NBA is no binding affinity was
observed when alanine was substituted in these positions. Study by Cancraenenbroeck et
a l.15
Compound

Peptide Sequence

IC50 (nM)

2 .1

Ghrelin(l-28)

10.5

2 .2

Ghrelin(l-23)

36.1

2.3

Ghrelin(l-14)

219.1

2.4

[A3] Ghrelin(l-14)

NBA

2.5

[A4 ] Ghrelin(l-14)

NBA

2 .6

[Ag] Ghrelin(l-14)

33.9

2.7

[Y8] Ghrelin(l-14)

21.8

The positioning of the acetylated side chain off residue 3 has been studied by
modifying ghrelin’s N-terminal amino acids (Table 2.2)74. When reducing the distance in
2.13 by deleting Ser2, ghrelin’s binding affinity is greatly reduced. In contrast, when
replacing Gly1 and Ser2 with 5-aminopentanoic acid (Ape), the binding affinity was
similar to that of 2.10. This data suggests Gly1 and Ser2 act as a spacer to facilitate
binding to the GHSR74. In addition, the free N-terminus of Gly1 in 2.9 was evaluated by
comparing it to acetylated 2.15. Acetylated 2.15 was 20-fold less potent then 2.9,
suggesting a positively charged N-terminus improves ghrelin’s binding affinity75. In
addition to modifying the N-terminus of ghrelin, the C-terminus has been altered by
changing the native carboxylic acid to an amide moiety. Amide 2.12 displayed enhanced
binding affinity over acid 2.1174. From this is was concluded a truncated ghrelin(l-5)
(2.12) was the shortest peptide chain responsible for eliciting a biological response to the
GHSR75.
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Table 2.2. The Importance of Gly1 and Ser2 in ghrelin analogs. Study by Matsumoto et
Compound

Peptide Sequence

ECS0 (nM)

2 .8

Human Ghrelin(l-28)

1.3

2.9

Ghrelin(l-14)

19

2 .1 0

Ghrelin( 1-7)-amide

2.6

2 .1 1

Ghrelin(l-5)

68

2 .1 2

Ghrelin( 1-5)-amide

6.2

2.13

Desacyl-Ser2-Ghrelin( 1-7)-amide

380

2.14

[Nrt-Ape] Ghrelin(3-7)-amide

3.4

2.15

[N"-acetyl] ghrelin(l-14)

>10,000

Ghrelin is the first natural peptide observed to contain an acylated side chain, with
most of the existing research focused on exploring the role of this unique functionality .
Recently, spectroscopic studies have shown that the octanoylated side chain and the Phe4
residue to be required for receptor binding70. Placing the acylated side chain on other
serine residues (Ser2, Ser6, Ser18) in human ghrelin proved to be detrimental to the binding
affinity (Figure 2.6.a,b,c,d)76. In the absence of the acylated side chain, desacyl-ghrelin
displayed a complete loss in of affinity for the GHSR, which inherently confirms the
importance of the lipophilic chain (Figure 2.6.e)70. Additional D- or L-amino acids have
been substituted in place of the Ser3 residue. However, the unnatural amino acid 2,3diaminopropionic acid (Dpr) is the only viable option which has not been detrimental to
binding affinity (Figure 2.6.f)73.
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Figure 2.6. IC50 values reported for modified ghrelin(l-28) analogs. Results show the
importance of the acylated side chain to the GHSR binding affinity. Positioning the
acylated side chain towards the N-terminus (b) shows a loss in binding affinity. A
substantial decrease in binding affinity is observed in analogs where the side chain is
positioned towards the C-terminus (c and d). In the absence of the acylated side chain (e)
binding is reduced. Replacing serine with 2,3-diaminopropionic acid (Dpr) (f) shows a
relatively small change in binding affinity to the GHSR.

2.3.1 Incorporating an Optical Imaging Agent into a Modified Ghrelin Peptide
Optical imaging agents are used to evaluate the performance of an imaging probe
in vitro before proceeding with radiolabelling methodologies. Using an optical dye in
initial studies can assess the potential of the imaging agent for targeting a specific
receptor. These moieties offer safer and easier methods for synthesizing imaging probes
and have longer shelf-lives then radioactive materials. However, fluorescent probes are
limited in value due to their low penetration depths of only a few centimeters through
tissue and thus are not suitable for in vivo imaging. For our purposes we used a
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fluorescein isothiocyanate (FITC) dye for our initial imaging agent. This dye has an
excitation wavelength o f 494 nm and emission of 521 nm.

2.4 Results and Discussion
The present study, discusses the synthesis of a ghrelin analogue and the
determination of the serum stability, receptor binding affinity, and potential use in the
imaging of GHSR-la receptors in live cells and fixed tissue. The ghrelin analogues were
designed to incorporate the most critical residues of human ghrelin, from amino acid 1 to
18, along with the replacement of residue 3 with Dpr. Truncating native ghrelin would
give a moderately small peptide, thereby enhancing the penetration depth and clearance
properties of the peptide. In addition, replacing Ser with the unnatural amino acid Dpr
had previously been proposed to enhance the peptides stability by limiting in vivo ester
hydrolysis78. It was also decided to change the C-terminal carboxylic acid with an amide
functionality by using a rink amide 4-methylbenzylhydrylamine (MBHA) resin. This
addition was to further improve the stability towards cellular exopeptidases, slowing the
metabolism of ghrelin in vivo.
The synthesis of [Dpr(octanoyl)3,Lys(fluorescein)l9]ghrelin(l-19)-amide 2.21 was
carried out in three steps. The 19 amino acid peptide sequence was synthesized manually
according to standard Fmoc-SPPS techniques (Scheme 2.1). The incorporation of Lys19 at
the C-terminus of the peptide provides a site of attachment for the fluorescein
isothiocyanate dye. Placing the optical dye near the C-terminus would greatly reduce the
interference with the N-terminal binding region of each ghrelin analogue, thereby
maintaining the binding affinity (Scheme 2.1).
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Scheme 2.1. Design of ghrelin(l-18)-amide peptides.

An orthogonal protecting group strategy was designed to allow for the selective
removal of Dpr3 and Lys19 side chain protecting groups for additional modifications to the
peptide (Scheme 2.2). For that reason, Dpr3 and Lys1.9 were protected with
allyloxycarbonyl (alloc) and 4-methyltrityl (Mtt) respectively (Scheme 2.1). All other
amino acids were protected using standard Fmoc orthogonal protecting groups that could
only be removed with greater than 50% trifluoroacetic acid. While still on resin, selective
removal

of

Dpr

(alloc)

was

accomplished

by

using

phenylsilane

and

a

tetrakis(triphenylphosphine)palladium(0) catalyst. The addition of octanoic acid to free
amine 2.17 afforded 2.18, which was characterized by HPLC-MS. Following this, the
addition of weak acid selectively deprotected the protected Lys19 side chain. Deprotection
of 4-methyltrityl (mtt) proved to be challenging and required multiple treatments of dilute
trifluoroacetic acid (2.5% TFA) solution in dichlormethane (DCM). A qualitative Kaiser
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test was performed after removing the Mtt protecting group to show the presence of free
amine 2.19 (Scheme 2.2).
When coupling fluorescein isothiocyanate (FITC) to amine 2.19 in DMF, a 1:1
ratio of unreacted starting material to product was observed. The use of DCM as an
alternative solvent significantly reduced this ratio, allowing for the reaction to occur more
efficiently (Scheme 2.3). At various time points, injecting micro-cleaved aliquots of the
reaction mixture onto an HPLC showed a decrease in starting material 2.19 and increase
in product 2.21 based on the UV-chromatogram.

Octanoic acid
HBTU, DIPEA, DMF
8 hrs

Scheme 2.2. Orthogonal Protecting group strategy for the synthesis of [Dpr(octanoyl)3,
Lys(fluorescein)19] ghrelin( 1-19)-amide.
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2.21

3
io
Scheme 2.3. Synthesis of [Dpr(octanoyl) , Lys(fluorescein) ] ghrelin(l-19)-amide.

An additional ghrelin(l-18)-amide 2.22 was synthesized according to the same
conditions as in scheme 2 with the absence of Lys19 and fluorescein component. This
analog was purified and later used as a blocking agent for cell studies. It was also
synthesized to compare the effect in binding affinities when incorporating a bulky dye at
the C-terminus of the peptide. Both synthesized analogs, fluorescein-ghrelin 2.21 and
ghrelin(l-18)-amide 2.22 were purified by HPLC-MS and isolated with yields of 15%
and 13% respectively (Table 2.3).
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Table 2.3. Ghrelin analogs with their purity, calculated, and observed mass.
m /z
C om pound

P u r ity %
P a r t ic le

C a lc

O b sd

2 .2 1

96

[M + H ]+

2 7 4 1 .3 1 7 9

2 7 4 1 .3 1 7 9

2 .2 2

99

[ M + 3 H ] 3+

7 4 4 .7

7 4 4 .3

^Compound 2.6 was characterized by electrospray ionization (ESI) time-of-flight mass
spectrometry (Mircromass LCT, Waters). Compound 2.21 was characterized by HPLCMS.

2.4.1 Serum Stability Studies on Ghrelin Analogs
To assess the stability of fluorescein-ghrelin 2.21 and ghrelin(l-18)-amide 2.22,
the peptides were incubated in rat serum over increasing time points at a constant
temperature of 37°C. Aliquots of each peptide were taken at different time points and
analyzed for peak intensity using HPLC UV chromatographic traces. The serum stability
of fluorescein-ghrelin did not differ significantly from that of native ghrelin, with a halflife of 27 minutes (Table 2.4). This validated the potential use of the probe in later ex vivo
imaging studies. Ghrelin(l-18)-amide 2.22 displayed a far better half-life of 83 minutes in
\

comparison to fluorescein-ghrelin 2.21 (Table 2.4). The shorter half-life of analogue 2.21,
is proposed to be due to enzymes initially degrading the pendent lysine side chain which
connects the fluorescein component (Figure 2.7).

2.4.2 Binding Assays
A receptor-binding assay using membranes overexpressing human GHSR-la was
developed by our collaborator Dr. Savita Dhanvnatari, in order to investigate the receptor
binding affinities of the fluorescein-ghrelin and ghrelin(l-18)-amide (Table 2.4). The
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Figure 2.7. Serum stability studies for fluorescein-ghrelin 2.21 (top) and ghrelin(l-18)amide 2.22. Half-lives were extrapolated and calculated at 50% (based on line of best
fit).
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binding affinity of fluorescein-ghrelin 2.21 was in the nM range, comparable to that of
native ghrelin and hexarelin, a known ligand that binds the GHSR-la.

Fluorescein-

ghrelin 2.21 was also within an order of magnitude of ghrelin(l-18)-amide 2.22 which
demonstrates the probes flexibility and tolerability for the addition of a bulky C-terminal
substituent.

Table 2.4. Binding affinity and serum stability of ghrelin and analogues. IC50 values are
means ± SEM (n=3-5). Values for serum half-lives represent the time point at which 50%
of the peptide remained as assessed by HPLC. ND, not determined.
Compound

IC50 (nM)

Serum half-life (min)

Ghrelin [1-28]

8.1 ± 1.0

27 (ref.7i>)

Hexarelin

6.4 ±2.4

ND

2 .2 1

9.5 ±2.6
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2 .2 2

1.3 ±0.4

83

2.4.3 Imaging Probe Studies in Cell and Fixed Tissue
In collaboration with the Dhanvantari and Lewis lab, we show for the first time
that a fluorescent ghrelin analogue can be used to image GHSR-la internalization. In one
study (Lewis Lab) fluorescein-ghrelin 2.21 was evaluated for its ability to target GHSRla expression in prostate cancer cell lines and to differentiate between benign and
cancerous tissue in fixed human prostate samples. A high background signal was
observed in earlier imaging experiments from the auto-fluorescence in prostate tissues,
making it difficult to confirm the specificity of the probe. To solve this problem the
hapten amplification technique was used to both amplify the signal and shift the detection
on

of the probe to the near infrared spectral window (Figure 2.8) .
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Two GHSR-expressing human prostate cancer cell lines, PC3 and LNCaP were
chosen to validate the affinity of the fluorescent probe. Binding of fluorescein-ghrelin
probe 2.21 was observed for both cell lines at the membrane and in the endosomal
compartment (Figure 2.9). The fluorescent probe was further blocked by the competitive
binding of unlabelled ghrelin(l-18)-amide 2.22, further demonstrating the formation of an
intemalized-ghrelin complex (Figure 2.10). The cells studies also confirmed our
fluorescein-ghrelin’s specificity towards the GHSR-la as no uptake was observed in non
expressing GHSR benign prostate hyperplasia (BPH) cells (Figure 2.9).

Figure 2.8. The hapten amplification technique is shown where an anti-fluorescein
antibody is incubated with the probe, followed by the addition of Alexa Fluor 647
secondary antibody. This approach amplifies the signal and shifts the detection of the
probe to the near infrared spectrum.
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Figure 2.9. Evaluation of fluorescein-ghrelin 2.21 binding and uptake in prostate cancer
cells (PC3 and LNCaP) and BPH cells. Nucleus stained with DAPI blue (upper panels).
Fluorescence micrograph of probe without overlaid DAPI stain (middle panel) and with
(lower panel). Graph shows the quantitative analysis of probe signal intensity in cells
lines. Scale bar 10 pm.
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Figure 2.10. Evaluation of fluorescein-ghrelin 2.21 and uptake in PC3 cells. Fluorescence
micrograph of PC3 cells incubated with fluorescein-ghrelin 2.21 in the presence (middle
and panels) and absence (upper panels) of excess ghrelin(l-18)-amide 2.22. Negative
control (lower panels) contained no fluorescent probe. Graph shows the quantitative
analysis of probe signal intensity with and without the presence of unlabelled ghrelin(l18)-amide 2.22. Scale bar 5 pm.
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binding affinity of fluorescein-ghrelin 2.21 was in the nM range, comparable to that of
native ghrelin and hexarelin, a known ligand that binds the GHSR-la.

Fluorescein-

ghrelin 2.21 was also within an order of magnitude of ghrelin(l-18)-amide 2.22 which
demonstrates the probes flexibility and tolerability for the addition of a bulky C-terminal
substituent.

Table 2.4. Binding affinity and serum stability of ghrelin and analogues. IC50 values are
means ± SEM (n=3-5). Values for serum half-lives represent the time point at which 50%
of the peptide remained as assessed by HPLC. ND, not determined.
Compound
Ghrelin [1-28|

IC 50 (nM)

Serum half-life (min)

±

27 (ref.7y)

8.1

1 .0

Hexarelin

6.4 ±2.4

ND

2 .2 1

9.5 ±2.6
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2 .2 2

1.3 ±0.4
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2.4.3 Imaging Probe Studies in Cell and Fixed Tissue
In collaboration with the Dhanvantari and Lewis lab, we show for the first time
that a fluorescent ghrelin analogue can be used to image GHSR-la internalization. In one
study (Lewis Lab) fluorescein-ghrelin 2.21 was evaluated for its ability to target GHSRla expression in prostate cancer cell lines and to differentiate between benign and
cancerous tissue in fixed human prostate samples. A high background signal was
observed in earlier imaging experiments from the auto-fluorescence in prostate tissues,
making it difficult to confirm the specificity of the probe. To solve this problem the
hapten amplification technique was used to both amplify the signal and shift the detection
of the probe to the near infrared spectral window (Figure 2.8) .
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To test the selectivity of our fluorescein-ghrelin probe for imaging prostate cancer
over benign prostate tissue, standard prostate samples were gathered from patients
undergoing radical prostatectomies in the Department of Urology at the London Regional
Health Science Centre. Ex vivo prostate tissue was confirmed by pathological reports and
divided into three catagories: (a) PCa, (b) paraepithelial neoplasia (PIN) and (c) BPH
tissue. The fluorescein-ghrelin 2.21 probe was able to distinguish between PCa tissue and
normal adjacent tissue (Figure 2.11). The selectivity of our probe was additionally
observed by its ability to differentiate between PCa and BPH. To our knowledge this is
the first example where prostate cancer tissue has been selectively differentiated from
benign tissues through the use of a receptor targeted imaging agent.
A subsequent study in collaboration with the Dhanvantari lab looked at GHSR-la
expression within a murine model. This study was based on a recent finding showing an
increase in GHSR-la expression within the myocardium of patients suffering congestive
heart failure*1. Western blot analysis revealed the strongest expression of GHSR-la to be
within the heart and brain. More importantly, GHSR-la expression was not evident
within organs such as the liver, stomach, kidney, pancrease, intestine and spleen ’ . Our
initial results presented a new possibility of using our modified ghrelin probe for imaging
cardiac pathology. This was tested by incubating fluorescein-ghrelin alone in murine
heart tissue, or with excess unlabelled ghrelin(l-28) or hexarelin added. Interestingly,
heart tissue incubated with fluorescein-ghrelin alone was brightly fluorescent, where as
lower fluorescence was observed when adding excess ghrelin(l-28) or hexarelin. The
blocking of fluorescence with ghrelin(l-28) or hexarelin indicated the specific binding of
our probe to GHSR-1a in the heart.
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Figure 2.11. Evaluation of fluorescein-ghrelin 2.21 probe in ex vivo human prostate
biopsy tissue. Preferential uptake was found in PIN and PCa, as compared to normal
prostate and BPH. Scale bar 10 pm.
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Figure 2.12. In situ binding of fluorescein-ghrelin in murine heart tissue. Binding of
fluorescein-ghrelin alone (a), or in the presence of ghrelin (b) or hexarelin (c). Auto
fluorescence shown in (d).

2.5 Conclusions
The objective of this preliminary study was to design and synthesize an optical
imaging probe. Two analogues of modified ghrelin were synthesized to incorporate the
most critical residues of ghrelin. The fluorescein-ghrelin imaging probe 2.21 showed a
9.5 nM binding affinity as well as a similar half-life to that of native ghrelin. The addition
of a fluorescent probe through a pendent lysine side chain was not detrimental to ghrelin’s
binding affinity and further demonstrated the flexibility and tolerability of our probe.
Internalization of the probe was visualized using two different cell lines that were known
to express the GHSR-la. Ex vivo human prostate tissue treated with the fluoresceinghrelin probe 2.21 demonstrated high selectivity in differentiating prostate cancer from
indolent disease. In addition to this study, the probe demonstrated binding to normal
murine heart tissue. This initial result raises the possibility of using this probe for
monitoring heart disease in patients with cardiomyopathy.
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These results have set the stage by validating our probe for use in in vitro and ex
vivo imaging. More importantly, the present study allows for future modifications to
ghrelin(l-18)-amide

2 .2 2

by incorporating other dyes or chelators for a new use in

positron emission tomography (PET).

2.6 Experimental
2.6.1 Materials and Equipment
All chemicals and solvents were purchased from Sigma-Aldrich Chemical Co.,
Peptides International, VWR or Fisher Scientific and were used without further
purification unless noted. High-resolution mass spectra were obtained on a Finnigan
MAT 8400 Mass Spectrometer (El), Micromass LCT Mass Spectrometer (ESI). Lowresolution mass spectra were obtained on a Micromass Quattro Micro API (MS-ESI and
LC-MS-ESI). Anhydrous DCM was prepared by distillation from CaH under argon.
Oven-dried or flame dried glassware was used in water sensitive reactions with the flow
of argon. Analytical HPLC was performed using a Grace Vydac Protein/Peptide RP-C18
column 4.6 x 250 mm, 5 pm or a Sunfire RP-C18 column 4.6 x 250 mm, 5 pm.
Preparative HPLC was performed using a Grace Vydac Peptide/Protein SP-C18 column
22.0 x 250 mm, 10 pm or a Sunfire SP-C18 column 22.0 x 250 mm, 10 pm. A gradient
system was used: water + 0.1% TFA (solvent A) and CH3CN + 0.1% TFA (Solvent B).
The absorbance was detected in the 200 nm to 500 nm wavelength range.

2.6.2 General Procedure for Peptide Assembly
Fully protected resin bound peptides were synthesized manually according to general
procedures in Fmoc solid phase peptide synthesis14. Fmoc protected rink amide MBHA
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resin (loading 0.56 and 0.47 meq/ g) was used as the solid support. N-Fmoc amino acids
with strong acid labile protecting groups for side chain functional groups, were used in
general, and N-Boc amino acids were used for the N-terminus. Fmoc-Dpr3, with the Pamine protected with allyloxycarbonyl (alloc), was used for residue-3. Fmoc-lysine (Lys),
with the P-amine protected with 4-methyltrityl (Mtt), was used for residue-19. Fmoc
removal was achieved by adding 20% piperidine in DMF for 5 and 15 minutes, followed
by successive washes with DMF and DCM after each treatment. For each amino acid
coupling, resin was treated twice with 3 eq. of Fmoc or Boc amino acids, 3 eq. of 3[bis(dimethylamino)methyliumyl]-3//-benzotriazol-1-oxide

hexafluorophosphate

(HBTU) and 6 eq. of N,N-diisopropylehtylamine (DIPEA) in 2 mL of DMF for 30
minutes to 2 hours. Couplings were followed by multpile washes with DMF, and DCM.
Using this general procedure, peptides were prepared on resin.

2.6.3 General Procedure for Selective Deprotection’s and Resin Cleavage
Selective deprotections were carried out using an orthogonal deprotection strategy
for residues 3 and 19. The P-amine protected with allyloxycarbonyl (alloc) was
selectively

removed

by

shaking

the

resin

with

0.35

eq.

of

tetrakis(triphenylphosphine)palladium (Pd(PPh3)4), and 20 eq. of phenylsilane (PhSiHj)
in 2 mL of dry DCM. This treatment was repeated twice, followed by successive washes
with DMF, and DCM. The P-amine protected with 4-methyltrityl (mtt) was selectively
removed by shaking the resin with

2% trifluoroacetic acid (TFA), and 5%

triisoproylsilane (TIS) in DCM for 2 minutes. This treatment was carried out 8 times,
followed by multiple washes with DMF, and DCM. The Kaiser test was used to monitor
the presence or absence of a free amine. After modifications towards the peptides were
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completed, the peptide was deprotected and cleaved from the resin using 95% TFA, 2.5%
TIS, and 2.5% water for 3-6 hours. The resin was filtered and rinsed with a small amount
of TFA. Cold tert-butyl methyl ether (TBME) was added to the filtrate to form a
precipitate. Following the addition of TBME, the slurry was centrifuged and decanted.
The peptide was rinsed with TBME and collected again. The solid was dissolved in water
with the addition of acetonitrile (ACN) when needed, froze and lyophilized to obtain a
crude peptide as a powder. Purification was carried out using preparative HPLC, and the
purity of the isolated product was determined by analytical HPLC.

2.6.4 ¡Dpr (Octanoic acid)J/Lysl9(Fluorescein)/ghrelin(l-19)-amide (2.21)
[Dpr3(alloc)][Lysl9(Mtt)]ghrelin(l-18) 2.1 was manually synthesized according to
the general procedure for peptide assembly. Selective alloc deprotection was performed
on residue-3 of 2.1 according to the general procedure to obtain a free amine 2.2.
Octanoic acid was coupled to the peptide to obtain 2.3 according to the general procedure
for peptide assembly. Selective Mtt deprotection was performed on residue-19 to give the
free amine, according to general procedures. Fluorescein isothiocyanate (FITC) (0.2
mmol, 0.078 g) was coupled to the peptide with the addition of 3 eq. DIPEA in 2 mL of
DMF. Following this, a final cleavage and deprotection was conducted according to the
general procedure to obtain the crude peptide. Purification was performed by HPLC
(gradient 30-60% solvent A in B) to obtain 2.6 with a 15% yield as a yellow powder
(ESI-MS and purity reported in Table 2.3).
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2.6.5 [Dpr*(Octanoic acid)]ghrelin(l-l8)-amide (2.22)
[Dpr3(alloc)] ghrelin(l-18) 2.1 was manually synthesized according to the general
procedure for peptide assembly. Selective alloc deprotection was performed on residue-3
according to the general procedure to obtain a free amine. Octanoic acid was coupled to
the peptide according to the general procedure for peptide assembly. Following this, a
final cleavage and deprotection was conducted according to the general procedure to
obtain the crude peptide. Purification was performed by HPLC (gradient 30-60% solvent
A in B) to obtain 2.7 with a 15% yield as a yellow powder (ESI-MS and purity reported
in Table 2.3).

2.6.6 Receptor Binding Assays 83
Binding assays were performed using cell membranes over-expressing recombinant
human GHS-R-la (Millipore). The binding reaction consisted of 5mg membrane, 30,000
cpm (0.037nmol/L) [1251]-ghrelin (Perkin Elmer), and a range of concentrations (10-6 to
10-11M) of hexarelin (a synthetic ghrelin with similar binding properties as endogenous
ghrelin), ghrelin(l-18) or fluorescein-ghrelin(l-18) in a total volume of 100 pL binding
buffer (50 mM Hepes, pH 7.4, 5mM MgCh, 1 mM CaCfj, 0.2% BSA, passed through a
0.45 pm filter). Total binding was determined by adding only [ I]-ghrelin and
membrane preparations to binding buffer. Tubes were incubated at 37°C with shaking at
500 rpm for 1 h, centrifuged at 13,000 rpm for 20 min and the pellet was washed once in
wash buffer (50 mM Hepes, pH 7.4, 500 mM NaCl, 0.1% BSA, passed through a 0.45 pm
filter) to remove any unbound radioactivity. The radioactivity in membrane pellets was
determined in a gamma counter, and binding curves (dose-response sigmoidal fit) were
generated in Graph Pad Prism 5. IC50 values for hexarelin, ghrelin(l-18)-amide 2.22 and
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fluorescein-ghrelin(l-18) 2.21 were determined as previously described*4. Each sample
was analyzed in triplicate and assays were repeated five times for all peptides.

2.6. 7 Serum Stability Study* ?
To assess the stability of 2.21 and 2.22 in serum, peptides (1 mg/ml peptide in acetate
buffer pH 6.2) was incubated in rat serum (final sample volume 0.5 ml; final peptide
concentration 20 mM) over increasing time points at 37°C. The incubation period ended
with the addition of 20 mL aqueous 10% TFA. Samples were then applied to C l8
reverse-phase cartridges (Light C l8 Sep-Pak, Waters), washed with 4 ml aqueous 0.1%
trifluoroacetic acid 6 (TFA), and eluted with 3 ml 70% acetonitrile in aqueous 0.1% TFA.
After lyophilization, samples were analyzed using analytical RP-HPLC, as previously
described*4. Half-lives of the peptides were calculated using Microsoft Excel.

2.6.8 Tissue Expression o f GHSR-la*3
All mice were treated in accordance with the guidelines set by the Animal Use
Subcommittee of the Canadian Council on Animal Care at the University of Western
Ontario. To determine the levels of GHS-Rla expression in various tissues, adult (8-10
weeks) female C57BL/6 mice were sacrificed using CO2 and heart, brain, liver, stomach,
kidney, pancreas, islets, intestine, and spleen were immediately removed. Protein was
or

extracted as described previously . Fifty mg of protein from each tissue were used for
Western blot analysis as described above, using rabbit anti-GHS-R (1:500, Santa Cruz
Biotechnology).
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2.6.9 Binding o f Fluorescein-ghrelin to heart tissue in situ83
Adult (8-10 weeks) female C57BL/6 mice were sacrificed using C02 and the hearts were
immediately removed and fixed in 4% paraformaldehyde (in PBS) overnight. Whole
hearts were then equilibrated in 30% sucrose in PBS, snap-frozen in Tissue-Tek OCT
using dry-ice cooled ethanol, and subsequently cryosectioned at 10 pm. Sections were
thawed in PBS and incubated for lh at room temperature in the following: 1 mM
fluorescein-ghrelin(l-18) alone; 1 mM of 2.21 with 100 mM ghrelin (Bachem); 1 mM of
2.21 with 100 mM hexarelin; or PBS alone to assess autofluorescence. Slides were then
rinsed 3X5 min in 9 PBS and viewed under a fluorescent microscope using the
fluorescein filter. Ten random fields of view were captured for each of 3 slides per tissue
per mouse.

2.6.10 Evaluation o f Fluorescein-ghrelin in PC3, LNCaP, and BPH cell lines86
PC-3 (CRL-1435, ATCC) cells were grown in F-12K medium (30-2004, ATCC)
supplemented with 10% fetal calf serum (FCS) and streptomycin (15 mg/ml). LNCaP
(CRL-1740, ATCC) were grown in RPMI (Invitrogen) with 10% FCS, streptomycin (15
mg/ml) and lx sodium pyruvate. BPH (generous gift from Dr. Michael Cox, VGH) were
grown in DMEM (Invitrogen) with 5% FBS and streptomycin (15 mg/ml). Cells were
grown on glass coverslips and frozen sections from prostate tissue samples were collected
onto poly-L-lysine-coated slides. Slides were fixed using 4% formaldehyde for 10
minutes at room temperature, and incubated with a 1/500 dilution of fluorescein-ghrelin
2.21 (1 mM/L) for 2 h at room temperature. The binding of fluorescein-ghrelin 2.21 was
amplified with an anti-fluorescein antibody (anti-fluorescein/Oregon Green mouse
monoclonal IgG antibody, A-6421, Invitrogen) and a secondary antibody (Alexa Fluor
647-R-phycoerythrin goat anti-mouse IgG, A-20990, Invitrogen). After incubation with
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the fluorescein-ghrelin 2.21, slides were incubated with a 1/500 dilution of the anti
fluorescein antibody (1 mg/mL) for 2 h at room temperature, and then incubated with a
1/2500 dilution of the secondary antibody (1 mg/mL) for 1 h at room temperature. The
nuclei in PC-3 cells and prostate tissue were counterstained with DAPI (D1306,
Invitrogen). The ghrelin probe and antibodies were diluted in PBS with 10% goat serum
and 1% bovine serum albumin to block the non-specific binding. For the assessment of
specific binding between fluorescein-ghrelin 2.21 and its receptor, a competitive blocking
study was performed in the presence of 10 times concentration of unlabeled ghrelin(l18)-amide 2.22. For negative control of ghrelin probe staining, the series slides with same
areas were incubated without fluorescein-ghrelin 2 .21 , but with the antifluorescein
antibody and the secondary antibody.

2.6.11 Evaluation o f Fluorescein-ghrelin in ex vivo prostate samples
To assess the selectivity of the fluorescein-ghrelin 2.21 for prostate cancer (PCa) over
prostate intraepithelial neoplasia (PIN) or benign tissue, standard prostate sextant biopsy
samples were collected from fresh surgery specimens of 13 patients undergoing radical
prostatectomy in the Department of Urology at the London Health Sciences Centre. The
prostate core biopsy samples were embedded in OCT immediately after collection and
stored at -80°C, until processed for serial frozen sections. For each block, one serial
frozen section slide underwent hematoxylin and eosin (H&E) staining and was subjected
to pathological analysis (Department of Pathology, UWO), and another serial section was
used for ghrelin probe staining. Prostate tissue was categorized into PCa, PIN or benign
tissue based on the pathological changes in H&E staining. Ghrelin probe staining in the
equivalent area on the adjacent serial section was quantitatively analyzed as described
below. This study obtained approval from an independent local Ethics Committee (UWO
REB #16840E), and obtained the informed consent from all patients for the research use
of their tissues.
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2.6.12 Quantitative Analysis for ghrelin analogue binding

Fluorescein-ghrelin(l-18) staining was captured by fluorescence confocal microscopy and
quantified by image analysis (Volocity 5.0, PerkinElmer). The signal intensity in a
selected region of interest (ROI) was calculated in relative fluorescence units (RFU) per
pixel. For the cancer cell staining, 20 images were captured for each experimental group
for quantitative analysis. The region of interest was established using bright field images,
and the mean signal intensity of each group was calculated. Negative controls were
incubated with no ghrelin probe but otherwise treated equivalently. For tissue staining,
the signal intensity of fluorescein-ghrelin 2.21 was normalized by the signal intensity in
the series negative control slides with the same area (normalized signal intensity = signal
intensity ghrelin - signal intensity negative control). For tissue slides, regions of interest
were selected manually consisting only of prostatic epithelium. Three fields were
captured from each slide, and up to 3 ROIs were selected per field for quantitative
analysis. A total of 167 images from 76 human prostate tissue slides were analyzed
quantitatively. The mean signal intensity for each histological feature was first calculated
on a per-patient basis, and these values were then averaged to determine the mean signal
intensity of each group.
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C hapter Three: The Design and Synthesis o f a G allium -68 Labelled
G hrelin A nalogue for PET N uclear Im aging
3.1 Introduction
There has been growing interest in designing radiolabelled peptides to significantly
improve the detection of disease, through the targeting of peptide receptors 87 ’88 ’89 ’90 ’91 . A
number of peptides labelled with varying radionuclides such as Ga,

Ga, F, Y,

In

and 64Cu have been investigated92,93,94,95,96. I8F-FDG, being the front-runner of PET
radiopharmaceuticals, has gained popularity in diagnosing a wide-range of malignant
diseases within the clinic97. It’s use in staging and re-staging of malignant disease(s) is
due to its high specificity and simplicity in production syntheses. However, F-FDG does
have its limitations when (a) imaging tumours with high differentiation and low growth
rates such as prostate carcinomas, (b) evaluating tissues located within or adjacent to high
metabolic activity or physiological accumulation (bladder), and (c) distinguishing
malignant tissue from inflammatory diseases . Furthermore, the intricate chemistry of
incorporating radioactive fluorine-18 into a biomolecule is rather challenging and limited
QO

#

when not having access to onsite cyclotron facilities . To overcome these limitations,
much of the existing research has focused on developing new radiopharmaceuticals for
the detection of cancer. An alternative approach, when not having access to a cyclotron
facility, is the use of an in-house generator system. Generator systems are a cost-effective
approach to storing radionuclides such as

Ga,

Rb, and

Cu . Although, the

^Germanium/^Gallium (68Ge/68Ga) generator has been around since the 1970s, the use of
gallium-68 for positron emissions tomography (PET) nuclear imaging has only recently
been investigated100,101,102,103,104. The generator functions by storing a long-lived parent
isotope, which decays to a short-lived daughter isotope. In 68Ge/68Ga generators, 68Ge is
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produced from a cyclotron by the (p, 2n) reaction on a 69 Ga target32 . Germanium-68 acts
as the parent isotope source with a half-life of 270 days, giving the system an adequate
lifetime for the synthesis of many labelled molecules (Figure 3.1). Furthermore, a
purification strategy based on the different chemical properties of the isotopes is used to
elute off 68Ga in the presence of 68Ge. This separation technique of removing 68Ge from
68Ga is critical to avoid the breakthrough of unwanted 68Ge in the imaging agent. In most
cases, an acidic solution of hydrochloric acid is used to elute off the 68Ga3' 99.
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Figure 3.1. The production of (,xGa through the (p, 2n) reaction with 69Ga.

Gallium-68 is a positron-emitting radioisotope that decays by 89% positron
emission and 11% electron capture. Among its 30 isotopes, two non-radioactive isotopes
of gallium exist; gallium-69 and gallium-70, with natural abundancies of 60.11% and
39.89% respectively32. Importantly, gallium-68 has a positron emission energy of 1899
keV, which is higher than that of fluorine-18. This higher positron energy can potentially
lead to a lower spatial resolution for a PET image . In comparison to other radioisotopes,
the 68 minute half-life makes it compatible with the pharmacokinetics of most
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radiopharmaceuticals including peptides and oligonucleotides105. Furthermore, a labelling
kit procedure for incorporating gallium-68 into biomolecules has been investigated
allowing for wide availability106.
In solution, Ga3' ions act as a hard Lewis acid, forming thermodynamically stable
complexes with ligands that are hard Lewis bases. Hard Lewis bases include ligands
containing nitrogen and oxygen, such as carboxylates and amines. Thus, in order to
incorporate Ga3' into the backbone of a biomolecule, a chelator system must be used to
coordinate the gallium. In addition to its ligand binding properties, the type of chelator
becomes imperative when attempting to maintain gallium’s thermodynamic stability
towards hydrolysis and kinetic inertness during in vivo use". Generally, most chelators
designed to coordinate Ga3' adopt a hexadentate model. This can be seen through the
cystal structure of 1,4,7,10-tetraazacyclodecane-TV,7V’,/V”,Ar ”-tetraacetic acid (tris-tbutylDOTA); a commonly used chelator; adopting a N4O2 encapsulated pseudooctahedral
gallium-DOTA complex107.
<xGa-DOTA-TOC, an octreotide peptide, has recently shown a number of
promising properties when labelled with gallium94,108. In one study, 68Ga-DOTA-TOC
was compared with 18F-FDG in patients who had confirmed neuroendocrine tumours
(NET)108. Based on qualitative analysis, 68Ga-DOTA-TOC displayed tumour uptake in
57/63 lessions, where as IXF-FDG only displayed uptake in the 43/63 lessions. In an
additional study, higher tumour uptake as well as lower kidney uptake was observed
when compared with other radiolabelled pharmaceuticals94.
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3.1.1 The Design and Synthesis o f a Gallium Ghrelin Analogue
Based on the design and synthesis of truncated peptides that bind well to the
GHSR, we investigated the design and synthesis of a gallium labelled ghrelin analogue
used for PET nuclear imaging ’ ’ . In our preliminary study described in chapter two,
the fluorescein-ghrelin analogue demonstrated a strong binding affinity to the GHSR
when positioning the fluorescein dye within the C-terminus of modified ghrelin. It
became clear that in order to maintain ghrelin’s high binding affinity when designing
modified analogues, placement of the bulky substituent had to be within sufficient
distance of the N-terminal amino acid binding region of ghrelin. Additionally, ghrelin’s
unique octanoylated side chain off residue three was required for its’ strong binding
affinity to the GHSR.
Recently, Matsumoto et a/.14 reported a low nM binding affinity for a truncated
ghrelin(l-5)-amide analogue, however in a preliminary study we demonstrated that upon
functionalization, these analogues display poor binding affinities of greater then 2000
nM39. In order to maintain potent receptor recognition, this study suggested that larger
peptide sequences were required when derivatizing ghrelin analogues. Thus, as in the
synthesis of fluorescein-ghrelin 2 .21 , an 18-mer amino acid sequence was designed to
incorporate the most critical amino acids for receptor recognition.
The addition of Lys19 on the C-terminus of ghrelin provided a site of attachment
for the metal chelation system. Placing the metal chelator on the C-terminus would limit
the interference between the N-terminal binding region of the peptide, thereby
maintaining potent binding affinity with the GHSR. As in previous syntheses, replacing
Ser3 with Dpr3 demonstrated a larger serum stability half-life of 83 minutes in ghrelin(l18) 2.22 in comparison to native ghrelin’s 27 minutes. Furthermore the C-terminus was
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also converted to amide functionality by using a rink amide 4-methylbenzylhydrylamine
(MBHA) resin. As in both fluorescein-ghrelin 2.21 and ghrelin(l-18) 2.22, this addition
was further improved the stability towards cellular exopepsidase, slowing the probes
metabolism in vivo.

3.2 Results and Discussion
The synthesis of [Dpr(octanoyl)3, Lys(DOTA)l9]ghrelin(l-19)-amide 3.6 was
carried out in five steps. The 19 amino acid peptide sequence was synthesized manually
according to standard Fmoc-SPPS techniques (Scheme 3.1). As in the synthesis of
fluorescein-ghrelin 2 .21 , an orthogonal protecting group strategy allowed for further
modification to modified ghrelin. For this reason, Dpr3 and Lys19 were protected with
allyloxycarbonyl (alloc) and 4-methyltrityl (Mtt) respectively. All other amino acids were
protected using standard Fmoc orthogonal protecting groups.
While on resin, selective removal of the alloc protecting group proceeded in one
step using phenylsilane and a palladium catalyst to provide amine 3.2. Using standard
coupling condition, octanoic acid was added to free amine 3.2 to afford 3.3, which was
characterized by HPLC-MS (Scheme 3.2). The sequential deprotection of Mtt was carried
out by multiple washes using a weakly acidic solution of trifluoroacetic acid in
dichloromethane (DCM). A qualitative Kaiser test was performed to observe the presence
of free amine 3.4 off the Lys19 amino acid side chain (Scheme 3.2).
When coupling in tris-t-butyl-DOTA to analogue 3.4, an incomplete reaction was
observed when using the standard coupling reagent HBTU, based on HPLC-MS. As a
result, an alternative peptide-coupling reagent was used to carry out the addition of tris-tbutyl-DOTA to analogue 3.4. 0-(7-Azabenzotriazol-l-yl)-N,N,N’,N’-tetramethyluronium
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hexafluorophosphate (HATU) is similar in structure to HBTU, however has shown to
react faster with less epimerization during coupling and was found to give better yields
then when using HBTU109’110’111. Based on HPLC-MS, the addition of DOTA to analogue
3.4 using HATU, drove the reaction to completion to provide 3.5 (Scheme 3.2). The final
step in this synthesis, was the addition of concentrated acid to cleave the analogue from
the solid support to afford peptide 3.6 in a 7.7% yield (Table 3.1).

Repeated as needed

H ll
O
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20% piperidine, D M F

R2
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Scheme 3.1. Fmoc-SPPS synthesis of on resin [Dpr(alloc)3, Lys(Mtt)19]ghrelin(l-19)amide 3.1. All other amino acids were protected using standard Fmoc chemistry
protecting groups.
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Scheme 3.2. Synthesis of [Dpr(octanoyl)3, Lys(DOTA)19] ghrelin(l-19)-amide 3.6.

Table 3.1. [Dpr(octanoyl)3, Lys(DOTA)19] ghrelin(l-19)-amide 3.6 calculated and
observed exact mass, and purity determined after HPLC purification.
Compound

Purity %

3.6

9 7 .4

Particle

m/z
Calc

Obsd

[ M + 4 H ] 4+

6 8 7 .6 5

6 8 7 .6 3
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The DOTA conjugated peptide 3.6 underwent coordination with nonradioactive
gallium nitrate hydrate in an aqueous buffered solution. Initially a reaction in a sodium
buffered solution at pH 5 was used to prevent hydrolysis and formation of Ga(OH4)'
complexes under aqueous conditions99’103’104. However, it was later determined that this
reaction did not require the buffered solution and could coordinate under neutral
conditions at moderate temperatures to form 3.7 (Scheme 3.3). Analogue 3.7 would later
be used as an internal standard in evaluating the incorporation of radioactive gallium-68.
The IC50 values for 3.6 and 3.7 were calculated to be 2.3 nM and 9.1 nM respectively,
which inherently confirmed that the positioning of the metal chelator did not affect the
binding interaction to the GHSR (Table 3.3).

Scheme 3.3. Synthesis of [Dpr(octanoyl)3, Lys(Ga69/70-DOTA)19] ghrelin(l-19)-amide
3.7.

Table 3.2. [Dpr(octanoyl)3, Lys(Ga69/70-DOTA)19] ghrelin(l-19)-amide 3.6 calculated and
observed exact mass, and purity determined after HPLC purification.
Compound

Purity %

3 .7

95.0

Particle

m/z
Calc

Obsd

r M + 3 H l3+

9 3 7 .1 0

9 3 7 .6 4
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Table 3.3. Comparing the binding affinities of synthesized ghrelin analogs to native
ghrelin.
Compound

IC50 (nM)

Ghrelin [1-28]

8.1 ± 1.0

3.6

2.3

3.7

9.1

3.2.1 The Design and Synthesis o f a Gallium-68 Radiolabelled Ghrelin Analogue
When designing peptide-based imaging probes for PET nuclear imaging, a
number of reaction parameters are required to be optimized before incorporating a
radionuclide source. In doing so, this technique limits the amount of radiation exposure
and thus creates a safer environment for the radio-chemist. In designing a fast and
efficient synthesis for incorporating gallium-68 into 3.6, we investigated the temperature
stability of 3.6 and purification techniques for removing additional side products. Based
on HPLC UV chromatograms, 3.6 displayed exceptional stability when being exposed to
a wide range of temperatures (Figure 3.2). Additionally, a purification method using a C18 sep-pack protocol was established to efficiently remove any residual gallium salts
from the reaction when forming 3.7.
Gallium-68 was eluted off of an ionic positron 6XGe/6XGa generator by using a 0.1
molar solution of hydrochloric acid, leaving behind the germanium-68 isotope. A 1 mg
sample of 3.6 was weighed out and dissolved in 1 mL of water. From this solution 100 pL
was taken and placed inside a lead shielded automated gallium synthesis box, run by
Modular-Lab software. 68Ga3+ in HC1 was added to the aqueous solution of 3.6 while
stirring at a temperature of 80 °C (Scheme 3.4). After 20 minutes of stirring, analogue 3.8
was injected onto a C-18 Sep-Pak " and eluted off with a 50% solution of acetonitrile and
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water. The completeness of the reaction was confirmed by lining up the UV HPLC trace
of standard 3.7 with the gamma trace of 3.8 (Figure 3.3). A 75% decay corrected
radiochemical yield was achieved for 3.8, based on the principle of first order decay
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Figure 3.2. Temperature stability study of [Dpr(octanoyl)3, Lys(DOTA)19] ghrelin(l-19)amide 3.6. Analogue 3.6 was dissolved in an aqueous solution at room temperature. At
ten-minute time intervals, aliquots of 3.6 were taken from the solution and injected onto
the HPLC to access the peptide’s stability. UV chromatograms show no decomposition in
analogue 3.6 when being exposed to various temperatures based on the peak retention
times.
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Scheme 3.4. The gallium-68 radiolabelling synthesis in forming [Dpr(octanoyl) ,
Lys(Ga68-DOTA)19] ghrelin(l-19)-amide 3.8.
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Figure 3.3. HPLC UV trace of non-radioactive standard 3.7 (bottom) and gamma trace of
gallium-68 labelled product 3.8 (top).

3.3 Conclusions
In this study a gallium-68 labelled ghrelin analogue (3.8) was designed and
synthesized. This is the first radiolabelled ghrelin analog synthesized for PET nuclear
imaging. The high stability of 3.6 in a wide-range of temperatures and ease of
purification, allowed for the radiolabelling process to be completed in a timely efficient
process. In the future, this will help assist in the preparation of high specific activity
product, a requirement for evaluating 3.8 in animal models. The 2.3 nM and 9.1 nM
binding affinities calculated for both unlabelled 3.6 and gallium labelled 3.7 respectively,
demonstrate the ability to incorporate a radio-metal chelator while maintaining potent
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receptor recognition to the GHSR. In addition, these compounds have not been optimized
for in vivo or pharmacokinetic stability, which may further improve their affinity and
stability to the GHSR. Nonetheless, a labelling strategy for incorporating gallium-68 into
the C-terminus side chain of modified ghrelin is an important preliminary step, when
designing radioactive peptide-based imaging probes.

3.4 Experimental
3.4.1 Materials and Equipment
All chemicals and solvents were purchased from Sigma-Aldrich Chemical Co., Peptides
International, VWR international or Fisher Scientific and were used without further
purification unless noted. High-resolution mass spectra were obtained on a Finnigan
MAT 8400 Mass Spectrometer (El), Micromass LCT Mass Spectrometer (ESI). Lowresolution mass spectra were obtained on a Micromass Quattro Micro API (MS-ESI and
LC-MS-ESI). Anhydrous DCM was prepared by distillation from CaH under argon.
Oven-dried or flame dried glassware was used in water sensitive reactions under argon. A
Eckert and Ziegler 6XGe/68Ga generator was used for the production of radioactive
gallium. The radiolabelling synthesis was done on an automated synthesis unit using
Modular Lab Software 4.0. A Waters symmetry, 4.6 x 150 mm, 5 A, C-18 column was
used and coupled to a gamma detector. This system employed a Waters 1525 Binary
HPLC pump, Waters 2487 dual X absorbance detector, Waters In-Line degasser and
Breeze software (version 3.30). Analytical HPLC was performed using a Grace Vydac
Protein/Peptide RP-C18 column 4.6 x 250 mm, 5 pm or a Waters Sunfire RP-C18 column
4.6 x 250 mm, 5 pm. Preparative HPLC was performed using a Grace Vydac
Peptide/Protein SP-C18 column 22.0 x 250 mm, 10 pm or a Waters Sunfire SP-C18
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column 22.0 x 250 mm, 10 pm. A gradient system was used: ACN + 0.1% TFA (solvent
A) and H20 + 0.1% TFA (Solvent B). The absorbance was detected in the 200 nm to 600
nm wavelength range.

3.4.2 General Procedure for Peptide Assembly
Fully protected resin bound peptides were synthesized manually according to general
procedures in Fmoc solid phase peptide synthesis14. Fmoc protected rink amide MBHA
resin (loading 0.56 and 0.47 meq/ g) was used as the solid support. In general, N-Fmoc
amino acids with strong acid labile side chain protecting groups were used, and N-Boc
amino acids were used for the N-terminus. Fmoc- Dpr , with the (3-amine protected with
allyloxycarbonyl (alloc), was used for residue-3. Fmoc-lysine (Lys), with the (3-amine
protected with 4-methyltrityl (Mtt), was used for residue-19. Fmoc removal was achieved
by adding 20% piperidine in DMF for 5 and 15 minutes, followed by washes with DMF
and DCM after each treatment. For each amino acid coupling, resin was treated twice
with 3 eq. of Fmoc or Boc amino acids, 3 eq. of 3-[bis(dimethylamino)methyliumyl]-3//benzotriazol-1-oxide

hexafluorophosphate

(HBTU)

and

6

eq.

of

N,N-

diisopropylethylamine (DIPEA) in 2 mL of DMF for 30 minutes to 2 hours. Couplings
were followed by multiple washes with DMF, and DCM. Using this general procedure,
peptides were prepared on resin.

3.4.3 General Procedure for Selective Deprotection and Resin Cleavage
Selective deprotections were carried out using an orthogonal deprotection strategy
for residues 3 and 19. The P-amine protected as the allyloxycarbonyl (alloc) was
selectively

removed

by

shaking

the

resin

with

0.35

eq.

of
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tetrakis(triphenylphosphine)palladium (Pd(PPh3)4), and 20 eq. of phenylsilane (PhSiHs)
in 2 mL of dry DCM. This treatment was repeated twice, followed by successive washes
with DMF, and DCM. The P-amine protected with 4-methyltrityl (Mtt) was selectively
removed by shaking the resin with 2% trifluoroacetic acid (TFA), and 5%
triisopropylsilane (TIS) in DCM for two minutes. This treatment was carried out 8 times,
followed by multiple washes with DMF, and DCM. The Kaiser test was used to monitor
the presence or absence of a free amine. After peptide modifications were completed, the
peptide was deprotected and cleaved from the resin using 95% TFA, 2.5% TIS, and 2.5%
water for 3-6 hours. The resin was filtered and rinsed with a small amount of TFA. Cold
tert-butyl methyl ether (TBME) was added to the filtrate to form a precipitate. Following
the addition of TBME, the slurry was centrifuged and decanted. The peptide was rinsed
with TBME and collected again. The solid was dissolved in water, frozen and lyophilized
to obtain a crude peptide as a powder. Purification was carried out using preparative
HPLC, and the purity of the isolated product was determined by analytical HPLC.
\
3.4.4 Dpr3(octanoic acid)//Lys,9(DOTA)/ghrelin(l-19)-amide (3.6)
3.1 was manually synthesized on resin according to the general procedure for peptide
assembly. Selective alloc deprotection was performed on residue-3 of 3.1 according to the
general procedure to obtain a free amine. Octanoic acid was coupled to the peptide to
obtain 3.3 according to the general procedure for peptide assembly. Selective Mtt
deprotection was performed on Lys-19 to give free amine 3.4, according to the general
procedures. Tris-t-butyl-DOTA was coupled to the peptide using 3 eq. of HATU and 6
eq. of DIPEA. Following this, a final cleavage and deprotection was conducted according
to the general procedure to obtain the crude peptide. Purification was performed by HPLC
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(gradient 20-80% solvent A in B) to obtain

3.6 with

a yield o f 7.7% (21 mg) as a white

powder (ESI-MS and purity reported in Table 3.1).

3.4.5 [Dpr3(octanoic acid)]fLysI9(69// 1Ga-Dota)]ghrelin(.l-19)-amide (3.7)
In a 5mL round bottom flask, 400 pL of water was added to 3.6 (8.4 mg, 0.0030 mmol)
while stirring. Heat was applied to the reaction flask until a constant temperature of 60 °C
was reached. At this time, gallium nitrate (Ga(NC>3)3 (15.6 mg, 0.0613 mmol) was added
to the reaction flask. The resulting clear solution was stirred between 60-80 °C for 20
minutes. Passing the reaction solution through a Sep-PakK) purified gallium labeled 3.7.
The purification was achieved by using a gradient starting from 100% water (2 mL) and
then 70% Acetonitrile: 30% water (3x 1 mL fractions). The four samples were frozen and
lyophilized to obtain a white powder. HPLC traces (gradient 20-80% solvent A in B)
confirm 3.7 as a white powder (ESI-MS and purity reported in Table 3.2) in a 83% yield.

3.4.6 IDpr3(octanoic acid)//Lys,9(68Ga-Dota)/ghrelin(l-19)-amide (3.8)
To an oven dried conical glass vial was added 100 pL of precursor 3.6 (1 mg/mL
/:o

'y i

dissolved in a neutral solution of water), to which Ga was added. The reaction mixture
was then heated to 80 °C for 20 minutes. Prior to purifying 3.8, a C-18 Sep-Pak Kcartridge
was conditioned with 5 mL of ethanol and 5 mL of water. The crude reaction mixture was
then passed through the Sep-PakK, followed by an additional of H20 and EtOH solution.
The volume of the solution was then reduced to roughly 1 mL, by placing on a speed
rotaryevaporator. Product 3.8 was then analyzed using HPLC coupled to a gamma
detector and compared to the UV trace of non-radioactive standard 3.7. A 75%
radiochemical yield was calculated for 3.8, decay corrected.
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C hapter Four: T he Design and Synthesis o f Fluorine L abelled G hrelin
A nalogues For use in Positron E m ission T om ography

4.1 Introduction
4.1.1 Fluorine-18 in Recent Drug Developments
The incorporation of fluorine-18 into active biomolecules has emerged as a useful
technique for diagnosing cancer in positron emission tomography (PET) . Its 97%
positron decay and energy of 0.633 MeV, makes it a suitable candidate for PET imaging.
Among the many PET radionuclides, fluorine-18 has gained its popularity due to its: (a)
longer half-life in comparison to other PET isotopes (Table 4.1), (b) enhanced spatial
resolution from its relatively low positron decay energy, and (c) size similarities to the
hydrogen atom, allowing it to be more readily incorporated into a lead compound113.
While an estimated 15% of all pharmaceuticals contain fluorine, incorporating the
radioactive 1XF into a biomolecule for PET imaging is a daunting task when considering
the hazardous nature of the radioisotope and production timeframe114’115. Radiochemists
are continually studying new ways to effectively manage the clock by either limiting the
overall synthetic steps in the production of a radiopharmaceutical or optimizing the
lengthy purification procedures. Failure to optimize these radiolabeling techniques will
result in a loss of specific activity for imaging a particular disease in vivo. Nevertheless,
lx[F]-labelled compounds have become ideal imaging agents for PET nuclear imaging
based on their high specific activities and ability to incorporate into small molecules
(Table 4.2).
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Table 4.1. Commonly used positron emitting radionuclides114.
Isotope

Half-life (min)

82Rubidium
l5Oxygen
“Il-- . --------Nitrogen
11Carbon
18Fluorine
64Copper

1.26
2.03
9.97
20.3
109.8
768

Table 4.2. Selected fluorine-18
use 116,117,118,119,120,121,122,123
’
. . . . . .
Compound
—rs----------------- 8 .
[ FJFluoroethyltyrosine
5-[18F]Fluorouracil
18F]Fluoro-a-methyltyrosine
16a-[18F]Fluoroestradiol
6-[18F]Altanserin
(-)-6-[18F]Fluoronorepinephrine
--TÖ
FIFluorodeoxyglucose

Positron Energy
(MeV)
3.15
1.70
1.19
0.96
0.64
0.66
labelled

Positron Range
(nM)
1.7
1.5
1.4
1.1
1.0
n/a

radiopharmaceuticals

Synthetic Pathways
O-alkylation with
fl8F]fluoroethyl tosylate
Electrophilic fluorination
Electrophilic fluorination
Nucleophilic Displacement
Nucleophilic aromatic
substitution
Nucleophilic aromatic
substitution
Electrophilic fluorination

in

clinical

Clinical Use
Tumour imaging
Tumour imaging
Tumour imaging
Estrogen receptor
positive tumours
5HT2A receptors
Cardiac
sympathetic
innervation
Tumour Imaging

4.1.2 Synthetic Approaches for Incorporating Fluorine-18 into Biomolecular Vehicles
Fluorination reactions are considered more difficult in comparison to other
halogénation reactions, simply because most reagents containing fluorine are very toxic
and too reactive124. Additionally, the chemistry utilized to make compounds containing
fluorine-18 is different from that of non-radioactive fluorine-19. Fluorine-19 can be
characterized using standard spectroscopic techniques such as proton NMR, carbon
NMR, fluorine NMR and MS. In contrast, fluorine-18 is characterized by comparison
with a non-radioactive standard using techniques such as radio-thin layer chromatography
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(TLC) or HPLC. Additionally, radiochemical synthesis is subject to (a) small nano-molar
reaction scales, (b) radiation protection and exposure and (c) fast chemistry techniques

.

Reactions involving fluorine-18 are generally under non-equilibrium conditions and
proceed in a pseudo-first-order pathway because of the high concentration of starting
material present. Furthermore, selected radiolabeling procedures are under vigorous
reaction conditions using high boiling point solvents. This allows for successful

F-

fluorination of many precursor materials that would otherwise fail if using standard l9Ffluorination methods. Lastly, yields in radiochemical synthesis are not always the subject
of importance, as the overall concern is a safe and reliable method to produce at least one
dose for PET nuclear imaging125.
Over the past decade, synthetic methods used to incorporate fluorine-18 into
biologically

active

macromolecules

such

as

peptides,

proteins,

oligonucleotides; have shown it usefulness for PET imaging of disease

sugars

and

. Chemically,

fluorine can behave as either a nucleophile or electrophile when incorporating it into a
lead compound. Today, electrophilic reactions are considered a , classical way of
incorporating fluorine into a compound. This reaction is considered unfavourable due to
low specific activity (maximum radio chemical yield of 50% from [ F]F2 production)
and high reaction impurities. Though this method is less common, it did play a substantial
role in the development of two well-known PET nuclear imaging agents: [ F]FDG
(Scheme 4.1) and [ F]fluoro-L-Dopa
nucleophilic

fluorination

reactions

’ . In contrast to this classical method,

are

commonly used

today

in developing

radiopharmaceutical PET imaging agents. In this chapter, attention will be focused on
nucleophilic fluorination, as the author used this synthetic reaction to form
prosthetic groups.

F-labelled
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1o

.

.

Scheme 4.1. An electrophilic fluorination reaction using [ FJacetyl-hypofluorite in the
production o f[ISF]FDG 127.

The chemistry of nucleophilic addition reactions can be divided into two different
approaches; (a) direct fluorination and (b) indirect fluorination. Direct fluorination can be
defined as the “direct” introduction of fluorine-18 into a target molecule in one-step. The
latter method of

F delivery is referred to as a prosthetic group approach (indirect),

where a low molecular weight compound can be readily radiolabeled prior to being
incorporated into a target. This strategy is generally used in a multistep synthetic
approach when the complexity of a biological target can not tolerate direct labeling
methods126. For example, fluorine-18 labelling of large peptides and electron rich arenes
traditionally uses this indirect labeling method

. In these types of examples, the starting

material undergoes a substitution type reaction with the fluorine source to form the
prosthetic group. In order for the reaction to occur the starting material generally contains
a halogen (Cl, Br, or I), sulfonate (mesylate, tosylate, triflate, or nosylate) or ammonium
leaving group

. While the nucleophilic addition of fluorine occurs in one-step, a

deprotection step must follow in order to give the biomolecule a site of attachment to the
prosthetic group (Scheme 4.2). The advantages of this class of reaction are the
quantitative radiochemical yields and high specific activities of the labeled biomolecules
of interest.

68

* 1an8 FScheme 4.2. Synthetic steps used to reach an 18F-labeled biomolecule (blue) using
labeled prosthetic group (red). Nucleophilic aromatic substitution on a quaternary
ammonium salt proceeds from the addition of F', followed by a deprotection step and
then addition of the desired peptide sequence.

4.1.3 Production o f Fluorine-18
Nucleophilic fluorine ([l8F]F') is produced in high specific activity (185 GBq/
pmol) from a cyclotron, by proton irradiation of an

O enriched water target (Scheme

4.3). All bulk amounts of [l80]water are subsequently removed following the production,
in order for the [18F]fluorine to behave as a nucleophile. This process is accomplished by
loading the radioactive aqueous media into an anion-exchange column followed by
eluting off the [ FJfluorine using a weak potassium carbonate base (Scheme 4.3)

. The

residual water remaining from this process is further removed by azeotropic evaporation
using acetonitrile. Generally, cations such as kryptofix [2.2.2] are added to enhance the
nucleophilicity of the [lxF]fluorine and solubilize the nucleophile in polar aprotic media.
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Cyclotron Target
18F(H2180 ) in H2180
180<>,rt)18F on H2180
1. Absorbed onto anion exchange
column
2. Eluted with aq. K2C0 3 /K2.2.2

Azeotropic evaporation
with 2-3x acetontrile

18F(H20 )y
18
Scheme 4.3. Chart showing the production of [ F]fluorine starting from cyclotron
t
18
18
18
irradiation of O water ( 0(p,n) F reaction). Following this is a flow chart on the steps
taken to reach [ FJfluorine with limited amounts of aqueous solution present (y is less
then x). Adapted from Cai et al'n .

4.1.4 Designing a Method for Incorporating Fluorine-18 into Ghrelin Analogues
As previously mentioned, ghrelin has a unique structure containing an
octanoylated Ser ester residue, which is critical for binding to the GHSR . Although the
positioning of the acylated side chain cannot be altered, other bulky, flexible and
rigidhydrophobic groups have been added as alternatives76. A study by Bednarek et al.76
observed the relationship between the n-octanoyl group with its affinity to the GHSR-la.
Modified Ser3 side chains that resembled the size and shape of native 4.6 such as 4.8 and
4.9, yielded similar potencies to that of ghrelin (Table 4.3) .
When replacing the n-octanoyl group with acetyl 4.10, a 20-fold decrease in
receptor binding affinity to the GHSR was observed. Ghrelin in the absence of its side
chain in 4.7 showed an even greater decrease in receptor binding affinity, demonstrating
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the importance of the aliphatic group. More importantly, when exploring the possibility of
non-hydrophobic interactions with the GHSR as in 4.11 and 4.12, the addition of an
amino or halogen group, offered poor (4.11) or enhanced (4.12) receptor recognition.

Table 4.3. Various modifications to native ghrelin’s Ser3 side chain and their reported
binding affinities. A study by Badnarek et al16.
Compound

Ghrelin Sequence

4.6

Ghrelin(l-28)

4.7

Ghrelin(l-28)

4.8

Ghrelin(l-28)

R’ Modification
0

0.25
R ^O H
0

r/s° V
0

4.9

Ghrelin(l-28)

4.10

Ghrelin(l-28)

ICso (nM)

>10,000

4

0.87

0.12
o
>2,000
0

M e

>2,000

4.11

Ghrelin(l-28)

4.12

Ghrelin(l-28)

0.08

4.13

Ghrelin(l-28)

11

■'~ÂO
0

4.14

Ghrelin(l-5)-NH2

R ^o^V ^

55

0
4.15

Ghrelin(l-14)

9.6
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Furthermore, the tolerability and flexibility in modifying ghrelin’s side chain was
demonstrated by the addition of benzene 4.13, showing similar binding affinity to that of
native ghrelin.
Prior to the authors’ involvement in this project, non-radioactive fluorine bearing
ghrelin analogues were synthesized78. A preliminary study on the potential use of placing
fluorine into the aliphatic side chain of ghrelin was evaluated. Modified ghrelin analogues
were synthesized and optimized by replacing both the Ser3 residue with Dpr3 and the Cterminal carboxy acid with an amide moiety. Futhermore as Bednerak et al.

investigated

varying aliphatic side chain lengths, our group synthesized three different fluorinated
aliphatic side chains that were incorporated into the backbone of ghrelin(l-14)-amide
(Table 4.4).

Table 4.4. Various fluorine bearing ghrelin(l-14)-amide analogs and their reported IC50
values. N= 1,4, 7. Study by Rosita et a/.78
H
H -G S-N

O
FLSPEHQRVQQRKES

NH'

NH

Compound
4.16
4.17
4.18

N Modification
1
4
7

IC50 (nM)
147
39.6
27.9

This preliminary investigation displayed the use of ghrelin’s aliphatic side chain
as a potential site of fluorination. More importantly, the binding affinities of the
analogues improved as the side chain length increased (Table 4.4). These results
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demonstrated that fluorine bearing 14-mer ghrelin peptides had the potential to be
developed into PET imaging agents for the GHSR .
Chapters two and three of this thesis described both the design and synthesis of a
fluorescein and radiolabelled ghrelin analog. In both of these cases, the location of the
fluorescent probe and chelate (for gallium-68) was situated off a pendent lysine side chain
towards the C-terminus of ghrelin. Instead of further modifying the C-terminus of
ghrelin(l-18), we propose a new method for incorporating fluorine into modified ghrelin
probes. Similar to the preliminary report by Rosita et al.

the design of novel aliphatic

fluorine containing ghrelin peptides, the author of this thesis extends this approach by
further developing unique fluorine labeled analogues (Figure 4.1).

Replacing Ser3 by Dpr3

C-terminal Amide

!H

H-GS-i-N^JJ-j FLSPEHQRVQQRKES
---!--Amide functionality \ i/ V NH
Bulky fluorinated
for improved
i ■..cA
»
«
side chain
___U « a.
in vivo stability
Figure 4.1. Our design approach in modifying ghrelin(l-18) for the incorporation of
fluorine-18.

4.2 Results and Discussion
4.2.1 The Design o f Non-radioactive Fluorine Bearing Ghrelin Analogues
The first parameter in developing PET-based imaging probes is the design and
optimization of a variety of non-radioactive compounds. A lead candidate is then selected
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based on its binding affinity towards the receptor o f interest. This evaluation process
establishes the foundation in developing a successful PET imaging probe.

In order to maintain the highest binding affinity, the location of the radiotracer
becomes significant when designing radioactive probes. The rationale behind our design
focuses on the fluorination of unique side chains off residue-3 (Dpr3) (Figure 4.1). Our
group has previously reported this design to have no significant effect on ghrelins binding
affinity78. Bednarek et al. further demonstrated this by comparing native ghrelin’s 0.25
nM value to an improved 0.08 nM affinity when brominating the aliphatic side chain .
Instead of incorporating fluorine bearing octanoic acid analogs in residue-3 (Dpr ), we
have converted ghrelin’s natural aliphatic chain into an aromatic system. To our
knowledge only one other group has incorporated benzene into the side chain off residue
3 (Dpr3). In their study, the IC50 values were reported to be two-fold less then that of
native ghrelin76. However, instead of incorporating single aromatic ring systems as in
benzene, we have chosen to extend this to included naphthalene rings containing nonradioactive fluorine-19.

s

With evidence of the fluorescein-ghrelin 2.21 having the potential to become a
novel optical imaging agent, non-radioactive fluorine analogues were synthesized
manually according to our developed orthogonal protecting group strategy using SPPS
(Scheme 4.4). The replacement of Ser3 with the unnatural amino acid Dpr3 and the Cterminal amide addition were to ensure maximum in vivo stability against cellular
exopeptidases (Figure 4.1). Selective removal of the orthogonal Drp -alloc protecting
group was accomplished using phenylsilane and a palladium catalyst. Following this was
the addition of commercially available fluorobenzoic acid or 4-fluoro-l -naphthoic acid to
amine 4.20 using standard coupling conditions. Modified fluorine labeled ghrelin
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analogues 4.21 and 4.22 were cleaved from the rink amide support and purified using
HPLC-MS with yields of 8.5% and 7% respectively (Table 4.5)
IC50 values for truncated peptides 4.21 and 4.22 were calculated by the
Dhanvantari group (Table 4.6). The results confirmed that ghrelin(l-l8)-amide peptides
with fluorine-19 incorporated into the side chain of Dpr have slightly better binding
affinities then that of human ghrelin. From our preliminary results, it appeared that the
larger naphthyl ring in 4.22 provided enhanced receptor affinity as compared to that of
phenyl ring 4.21, further drawing our attention to developing more naphthyl labeled
ghrelin analogs.

P hS iH 3, Pd(PPh3)4
Boc —G S —N

FLSPEHQ RVQ QRKES— Q

----------------------------

B o c -G S -N

FLSPEHQ RVQ QRKES— ^

DCM , Ar(g)
NH;

4.20

4.19

1. HBTU, DIPEA, DMF, 3eq. A or B

2. 95% TFA, 2.5 TIS, 2.5% H20

F L S P E H Q R V Q Q R K E S -N H :

H -G S -

NH

1

R*

Scheme 4.4. Synthesis of ghrelin(l-18)-amide analogues with varying aromatic Dpr3 side
chains.
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Table 4.5. Fluorine bearing ghrelin analogues with their calculated and observed exact
mass, as well as purity determination after FIPLC purification.
m /z
C om pound

P u r ity %

4 .2 1

99.0
96.5

4 .2 2

P a r tic le

C a lc

O b sd

rM + 3 H l3+
fM + 3 H l3+

742.04
759.52

742.84
759.71

Table 4.6. Comparing the binding affinities of synthesized fluorine bearing ghrelin( 1-18)amide analogs to native ghrelin and hexarelin (mean ± s.d., n= 3)
Compound

IC50 (nM)

Ghrelin [1-28]

8.1 ± 1.0

Hexarelin

6.4 ±2.4

4.21

7.2

4.22

2.9

In an effort to determine the minimal binding sequence required for fluorine
containing

peptides,

further

structure

activity

relationships

were

undertaken.

Craenenbroeck et al.75 observed similar binding affinities to ghrelin(l-14) when replacing
Glu8 with Tyr8. Similar to their finding, a study by Matsumoto et a l73 showed potent
receptor recognition to that of human ghrelin with modified versions of ghrelin(l-8),
where improved potency for ghrelin(l-8) was achieved by replacing Glu with either a
lysine or arginine . From these studies, we propose that ghrelin could be further
truncated to an 8-mer peptide, as long as a hydrogen bond donor is located in position
eight.
To limit the overall renal uptake for our probe during in vivo animal studies, it is
suggested to avoid using lysine and arginine amino acids

. Instead tyrosine was

incorporated into the low weight ghrelin peptides in accordance to scheme 4.4.
Compounds 4.24, 4.25, 4.26 and 4.27 were synthesized manually using the orthogonal
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SPPS methodology. Commercially available fluorobenzoic acid, 4-fluoro-l-naphthoic
acid, 6-fluoro-2-naphthoic acid and octanoic acid were purchased and coupled into the
Drp side chain upon selective removal of the alloc protecting group. Upon cleaving,
peptides 4.24, 4.25, 4.26 and 4.27 were purified and characterized by HPLC-MS with
overall yields of 10%, 10%, 4% and 15% respectively (Table 4.7)

Boc - GS - N

f l s p y —Q

^NH
0^0^=*

1. PhSiH3, Pd(PPh3)4
DCM, Ar(g)
H- GS - N

FLSPY - NH2

2. HBTU, DIPEA, DMF,
3 eq of A, B, C or D
3. 95% TFA, 2.5% TIS, 2.5% H20

4.23

O

Scheme 4.5. The synthesis of low molecular weight [Tyr ]ghrelin(l-7)-amide analogues
with varying Dpr3 side chains.
Table 4.7. Fluorine bearing ghrelin analogues with their calculated and observed exact
mass, and purity determined after HPLC purification
C om pound

P u r ity %

4 .2 4

99.1
97.3
94.4
91.2

4 .2 5
4 .2 6
4 .2 7

m /z
P a r t ic l e

C a lc

O b sd

[M +H1+
[M +H1+
TM+H1+
iM + H f

980.46
1030.61
1030.61
984.06

980.85
1030.05
1029.75
983.99

Using a cellular binding assay, the affinities of the lower molecular weight
[Tyr ]ghrelin(l-8)-amide analogues were determined (Table 4.8). Interestingly, modified
ghrelin in the presence of a phenyl side chain as in 4.24, was discovered to have a poor
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receptor binding affinity to the GHSR. However, when increasing the bulkiness of the
aromatic ring as in naphthyl 4.26, the affinity to the GHSR dramatically increases. In
O

comparison to ghrelin[l-28] and [Tyr ]ghrelin(l-8) with the octanoylated side chain 4.27,
our novel naphthyl side chains show a similar affinity towards the GHSR. The 18-mer
and 8-mer novel peptide sequences have demonstrated the tolerability and flexibility of
human ghrelin for use in PET imaging. In addition to the low nM binding affinities
achieved by the placement of our unnatural aromatic side chains, we have developed an
integrated radiopharmaceutical, where the radioisotope is incorporated into the receptor
binding region of interest.

Table 4.8. Binding affinities to the
GHSR of low molecular weight [Tyr8]ghrelin(l-8)3
amide analogues with varying Dpr side chains. ND = Not determined.
Compound

IC50 (nM)

Ghrelin [1-28]

8.1 ± 1.0

4.24

435 ± 82

4.25

ND

4.26

9.9 ± 1.7

4.27

65 ±22

4.2.2 Designing an Integrated Radiopharmaceutical using Fluorine-18 prosthetic
groups
The development of a fluorine-18 labelled naphthalene prosthetic group was
investigated, since the binding affinities for both 18-mer and 8-mer naphthyl containing
peptides demonstrated potent binding affinity to the GHSR. To our knowledge, fluorine18 labelled naphthyl rings used as prosthetic groups have not previously been reported.
The synthesis of these novel prosthetic groups was investigated based on the results
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obtained from Tables 4.6 and 4.8. These prosthetic groups would be used to establish a
radiolabelling method for incorporating bulky side chains into the binding region of
modified ghrelin analogues. Although the use of naphthalene compounds as prosthetic
groups has not been studied, many successful radiochemical syntheses are reported for
similar aromatic targets (Scheme 4.6)

. These well-established reactions have been

applied to three different naphthalene compounds. Figure 4.2 displays the three targets we
have investigated, with the goal of labeling a naphthalene group, which displayed low nM
binding affinity in our modified ghrelin sequences. This would be the first example of a
ghrelin analog radiolabeled with fluorine-18 for PET imaging.

o
PG

1. 18F' source
►
2. Deprotection

4.28

p

18

4.29

Scheme 4.6. A general SnAr reaction involving the addition of fluorine to a protected
benzoic acid to afford lxF-fluorobenzoic acid130.

Incorporating fluorine-18 into an aromatic system requires a nucleophilic source
of fluorine, an electron-withdrawing group (EWG) and a good leaving group (LG).
Commonly used leaving groups for aromatic substitution reactions include: I< Br< Cl<
F< NO2 and N Me3

. In this chapter, we have chosen to use a quaternary ammonium

salt as the leaving group in the nucleophilic aromatic substitution reactions (SNAr)
(Scheme 4.6).
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6-Fluoro-2-Naphthoic Add

Figure 4.2. Novel Naphthalene prosthetic group targets.

The synthetic approach used in developing a fluorine-18 labelled prosthetic group
began with commercially available 3-amino-2-naphthoic acid. Amine 4.30 underwent a
reductive amination with sodium cyanoborohydride and formaldehyde in methanol
(MeOH) at room temperature to give 4.31 (Scheme 4.7). Sodium cyanoborodydride was
chosen as the reducing agent because of its mild and efficient ability at synthesizing
tertiary amines when in the presence of carboxylic acids131. A variety of different solvents
including dimethylformamide (DMF), acetonitrile (ACN), and methanol (MeOH) were
used in separate reactions all accounting for similar yields of 50% after purification. The
lower yields achieved in this initial step can be accounted for due to the presence of the
acid ortho to the amine. The electron withdrawing carboxylic acid could decrease the
nucleophilicity of the aromatic amine as well as make it less accessible to the hydride
source due to steric hindrance. Maintaining the pH at 3-5 through addition of acetic acid
shortened the reaction time from 24 hours to 6 hours as indicated by thin layer
chromatography (TLC). Other attempts were made to increase the yield by prolonging
reaction times and adding excess of reagents. These attempts proved to be unsuccessful
and resulted in 20% recovered starting material 4.30 and mono-substituted byproducts.
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o

O
NaCNBH3, Formaldehyde
-------------------------------►
MeOH, RT, 2 hrs, 50%

Scheme 4.7. Reductive amination of an ortho substituted amine.

Solubility issues limited 4.31 from undergoing a transformation to the ester. As a
result 4.30 was first protected under acidic conditions to give ethyl ester 4.32 in a 80%
yield (Scheme 4.8). Table 4.9 summarizes the three different approaches used to protect
carboxylic acid 4.30. Under reaction conditions a, a 42% yield was achieved through the
formation of an acid chloride intermediate followed by the nucleophilic attack of ethanol.
Monitoring this reaction by TLC showed the absence of starting material at 10 hours.
Upon basic work-up conditions the ethyl ester 4.32 was isolated using flash
chromatography. The low yield achieved under these conditions was caused by the
hydrolysis of the ethyl ester when using sodium carbonate in the work-up. Based on
proton NMR, addition of sodium carbonate to 4.32 showed a loss of peaks corresponding
to the ethyl ester protons. Selecting a weaker base at lower concentrations (sodium
bicarbonate) displayed a 10% improvement in isolating 4.32 (condition b) with a yield of
52% respectively. Instead of using SO2CI2 to produce the unstable acid chloride
intermediate 4.30, two alternative approaches using HC1 and H2SO4 were then used to
protect 4.30. When using additions of 10 molar hydrochloric acid and 12 molar sulphuric
acid, the protection of the free acid increased from 55% to 80% respectively. Thus,
sulphuric acid was chosen as the preferred reagent in forming 4.32.
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1. Reagent, EtOH, 0°C
►
2. Reflux, 80°C

4.32

4.30

Scheme 4.8. The synthesis of protecting carboxylic acid 23.
Table 4.9. Various reagents and conditions used for protecting 2-amino-3-naphthoic acid
4.30.
C o n d itio n

R eagent

Eq.

T im e (h rs)

Y ield (% )

a

s o 2c i 2

1.4

b

S 0 2C12

1.4

c

s o 2c i 2

42
52
52

d

HC1

2.5
5.0
5.0

10
10
24
24
24

e

h

2s

o

4

55
80

Reductive amination of the aromatic amine was carried out on 4.32 using the same
method previously established in Scheme 4.7. Initially, reductive amination of 4.32 only
formed the mono-substituted aromatic amine based on proton NMR. By constantly
adjusting the pH (3-5) of the reacting solution using acetic acid, di-substituted 4.33 was
isolated in a 75% yield (Scheme 4.9).

4.32

s

4.33 (75% )

M eOTf, Dry DCM,
Ar(g), 0°C

Scheme 4.9. Towards the synthesis o f an ortho quaternary ammonium salt.

4.34

82

Commercially available methyl triflate was used in anhydrous conditions in an
attempt to form the quaternary ammonium salt compound 4.35 (Scheme 4.9). In general,
reactions involving the formation of a quaternary salt are high yielding. Yet, in this
system, the electronics changed when placing an electron withdrawing group (EWG)
ortho to the site of methylation. In addition, poor solubility starting material 4.33 was
observed in a wide range of solvents including chloroform, DCM and tetrahydrofuran
(THF). When attempting to drive the reaction forward, salt 4.35 was not formed even
upon adding excessive amounts of methyl triflate.
With attempts at a synthetic route towards a radiolabeled precursor for 3-fluoro-2naphthoic acid remaining unsuccessful, we elected to move ahead and focus on 6-fluoro2-naphthoic acid. In this target compound the aromatic amine was assumed to be a better
nucleophile due to its positioning on the opposing ring to the EWG. Scheme 4.10 shows
the steps taken to form the quaternary ammonium salt using the same methods as reported
in the attempt to synthesize 3-fluoro-2-naphthoic acid. Aromatic amine 4.36 underwent a
reductive amination to the give tertiary amine 4.37 with a 64% yield. The quaternary
ammonium salt 4.38 was isolated in a 70% yield, upon being filtered from the reaction
mixture. When using precursor 4.37, solubility issues were not observed as in the latter
case of functionalizing amine 4.33.

4 .3 6

N aC N B H 3, Form aldehyde

M eOTf, Dry D C M

M eO H , R T, 2 hrs, 64%

0°C, 30 min, 70%

4.37

Scheme 4.10. The synthesis of a quaternary ammonium salt 4.38.

4.38
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This method of forming the quaternary ammonium ion was then re-applied to the
initial protected acid using 6-amino-2-naphthoic acid (Scheme 4.11). The protection of
4.36 using the optimized sulfuric acid conditions gave the corresponding ethyl ester 4.39
in higher yields then previously observed with having the substituents ortho to one
another. Amine 4.39 underwent a reductive amination to give the corresponding tertiary
amine 4.40 in a 64% yield. Alkylation of 4.40 using methyl triflate gave the quaternary
ammonium salt 4.41 in a 78% yield.
The remaining step in developing a radiolabeling method for 6-fluoro-2-naphthoic
acid (4.42) was introducing a cold fluorine source and observing the displacement of the
ammonium cation using NMR spectroscopy (Scheme 4.11). In general, an EWG is
required to achieve a good substitution yield for a SnAr reaction132. These substitution
reactions are highly dependent on solvent choice, reaction temperatures, reaction times,
amount of base and precursor concentrations .

Scheme 4.11. Precursor synthesis o f fluorine bearing prosthetic group.
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An initial reaction reported by Seimbile et al was attemped at room temperature
reaction using tetrabutylammonium fluoride (TBAF) in anhydrous acetonitrile133,134.
Based on proton NMR, the outcome of this reaction formed 50% of demethylated 4.43
and recovered ammonium salt 4.41. An additional reaction applying heat to 1.7
equivalents of TBAF in situ with starting material 4.41 resulted a 70% yield of 4.43. It
was anticipated that there would be formation of fluorinated 4.42 when applying more
vigorous reaction conditions. However, in a number of different solvents including
toluene, dimethyl sulfoxide, and dimethylformamide, a selective demethylation reaction
occurred to give 4.43 (conditions c-d).

Table 4.10. Summary of fluorinating agents used to displace the quaternary ammonium
salt 4.41.
C o n d itio n

S o lv e n t (m L )

R eagent

Eq.

T e m p . (°C )

T i m e (h rs.)

Y ield (% )

a

A C N (2 m L )

TBAF

1.0

RT

1.0

50

b

T H F (2 m L )

TBAF

2 .0

RT

1.0

0

c

T o lu e n e (2 m L )

TBAF

1.7

115

2 .0

70

d

T o lu e n e (6 m L )

TBAF

1.5

115

2 .0

—

e

D M S O (2 m L )

TBAF

1.1

185

1.5

65

Nucleophilic fluoride in all cases appeared to selectively favour the sp3 hybridized
methyl groups off the ammonium cation, rather then attacking the sp2 aromatic carbon.
This incomplete formation of fluorine bearing substituents suggests a relatively un
activated trimethylammonium triflate compound. The result of this reaction is
summarized by the competing SN2 reverse Menschutkin reaction134. Furthermore,
literature suggests these types of fluorination reactions are highly dependant on the
environment of the aryl ring(s) substituents135. In one study, the authors comment that the
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methyl groups on a quaternary ammonium cation are quite labile in the presence of
anhydrous fluoride

i o r

.

In order to access the standard fluorinated naphthalene prosthetic group,
commercially available 6-fluoro-2-naphthoic acid was protected using the same
conditions as in Scheme 4.8. Non-radioactive 4.45 would later be used as a standard for
comparison during the synthesis of the corresponding prosthetic group HPLC.

Scheme 4.12. Synthesis of standard fluorinated naphthalene.

4.2.3 Incorporating Fluorine-18
As previously mentioned, the chemistry of fluorine-18 can differ greatly from that
of non-radioactive fluorine because of its pseudo-first order kinetics. Thus, the
radiochemical synthesis using salt 4.41 was attempted, even though the introduction of
non-radioactive fluorine was unsuccessful in synthesizing standard 4.42. Nucleophilic
fluorine was produced from the

0(p,n) F reaction using the Lawson Health Research

Institute cyclotron facility at St. Joseph’s Hospital. The radioactive media was washed
from the cyclotron target and placed inside an enclosed lead hot cell for safety
precautions. The media was then passed through an anion exchange column and eluted
with a solution consisting of weak base and krytofix 2.2.2. The fluorine-18 solution was
then placed inside a Tracer-Lab FX F-E automated synthesis unit made by General
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Electric (Figure 4.3). This synthesizer allowed for the automated synthesis of compound
4.46 using Tracer Lab software, to limit the user from exposure to radiation.
To ensure limited amounts of water remained, acetonitrile was used to azeotrope
the sample. Following this was the addition of 4.41 dissolved in dimethyl sulfoxide
(DMSO) to the fluorine-18 media. A nucleophilic aromatic substitution reaction occurred
with salt 4.41 to give product 4.46 (Scheme 4.13). This was confirmed from the HPLC
UV trace of the standard 4.45 lining up with the gamma trace of 4.46 (Figure 4.4). Based
on the gamma trace of product 4.46, an unknown peak was present at 10 minutes. We
reason this peak to be a fluorinated derivative of naphthalene on another location within
the ring. Although this reaction is in its early stages, and purification methods have not
been developed, we have shown that fluorination can occur when the EWG is on the
opposing ring of naphthalene. Additionally, there was a large difference in retention times
based on F1PLC traces of precursor 4.41 and product 4.46 (Figure 4.5). This will lead to
an easy purification method using an automated sep-pack procedure.
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Helium Supply

Exhaust
Helium
supply

Needle
Vacuum
Reaction Flask
\

Figure 4.3. Schematic diagram of the Tracer Lab FX F-E system. Vials contained: Vial 1
(Vi) a 2mL solution of Kryptofix 2.2.2 and lfiF', Vial 2 (V2) a 2ml solution of anhydrous
acetonitrile and Vial 3 (V3) a solution of Starting Material dissolved in lmL anhydrous
DMSO. Synthesis began by transferring vial 1 contents to the reaction flask. Azeotropic
removal of residual water occurred by heating the reaction flask (under vaccum) with
acetonitrile from vial 2. Vial 3 was then be added (under helium) to the reaction flask,
starting the reaction.
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Scheme 4.13. Synthesis of an F-18 labeled novel prosthetic group.

1 70-

-1 72-

Î>

74-
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-1 78-

Minutes

Figure 4.4. HPLC UV trace of non-radioactive standard 4.45 (top) and gamma trace of
fluorine-18 labelled product 4.46 (bottom).
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Figure 4.5. HPLC traces of precursor 4.41 (top) and standard 4.45 (bottom).

4.2.4 Other Attempts at Designing Non-Radioactive Standards
In addition to fluorinating the opposing ring as in compound 4.41, we are
investigating the radio-chemical synthesis of 4-fluoro-2-naphthoic acid (4.54). This target
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has the most resemblance to that of benzene as both the EWG and leaving group are on
the same ring. Starting from N, N-dimethylaminonaphthalene (4.47), a glyoxal chloride
intermediate was formed from the addition of oxaylyl chloride and base (Scheme 4.14).
Decarbonylation of the glyoxal intermediate formed the corresponding acid chloride of
4.48. Two identical products were isolated using either pyridine (4.48a) or DABCO
(4.48b); however, pyridine resulted in a 40% yield over the 33% yield obtained from
DABCO (Scheme 4.14). Following this the quaternary ammonium salt (4.49) was
synthesized in a 70% yield (as discussed in previous schemes).

Scheme 4.14. Towards the synthesis of 4-fluoro-l-naphthoic ethyl ester.
s
In an effort to improve the low yields observed in the formation of compound
4.48, a new synthetic route was attempted. N, N-dimethylaminonaphthalene 4.47 was
added to a cold solution of trimethylorthoformate. The drop-wise addition of titanium
chloride, a strong hygroscopic Lewis acid, to 4.47 afforded aldehyde 4.50 in 80%.
Oxidation of aldehyde 4.50 to corresponding acid 4.51 was initially attempted in a
peroxide solution however, based on NMR spectroscopy the aldehyde peak was still
present. A method using a silver nitrate catalyst in acetonitrile was attempted, which also
failed to work136. The addition of potassium permanganate, a strong oxidizing agent,
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afforded acid 4.51 in a 57% yield.

The acid 4.51 was then protected under acidic

conditions to yield ethyl ester 4.52 by the method previously discussed. Subsequent
reaction steps are described in Scheme 4.15 which are proposed to ultimately form
fluorine-18 labelled naphthoic ethyl 4.46.

\
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Scheme 4.15. An alternative approach to synthesizing 4-fluoro-2-naphthoic acid.

4.3 Conclusions
The synthesis of 18-mer and 8-mer ghrelin analogues with modified Ser3 side
chains have been investigated based on their binding affinities to the GHSR. The
synthesized ghrelin analogues have demonstrated high affinity towards the GHSR even
when incorporating bulky fluorinated aromatic substituents. This has led to the
development of a radiolabelling strategy for incorporating fluorine-18 into a naphthalene
prosthetic group. It proved to be difficult to synthesize a fluorine-18 naphthalene ring,
when situating fluorine next to the electron withdrawing substituent. However when
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placing fluorine on the opposing ring, a nucelophilic aromatic substitution can occur. This
is the first example of the design, synthesis, and characterization of a radiolabelled
naphthalene analog used as a prosthetic group for the molecular imaging of disease. The
next step in the integrated design is to optimize conditions needed for integrating the
radiolabelled prosthetic group into the low molecular weight ghrelin analogues. These
analogues will then be tested in a murine model to validate their potential use as PET
imaging probes for cancer detection.

4.4 Experimental
4.4.1 Materials and Equipment
All chemicals and solvents were purchased from Sigma-Aldrich Chemical Co.,
Peptides International, VWR international or Fisher Scientific and were used without
further purification unless noted. Solution phase NMR sepctra ( H and C) were obtained
on a Varian Mercury 400 spectrometer. 'H and l3C chemical shifts were referenced with
the residual solvent resonances relative to trimethylsilane. High-resolution mass spectra
were obtained on a Finnigan MAT 8400 Mass Spectrometer (El) and Micromass LCT
Mass Spectrometer (ESI). Low-resolution mass spectra were obtained on a Micromass
Quattro Micro API (MS-ESI and LC-MS-ESI). Anhydrous DCM was prepared by
distillation from CaH under argon. Oven-dried or flame dried glassware was used in
water sensitive reactions under a flow of argon. The radiolabelling synthesis was done
using the Lawson Health Research Institute cyclotron facility at St. Joseph’s Hospital. All
fluorine-18 reactions took place in a Tracer-Lab FX-FE (General Electric) automated
synthesis unit, using tracer lab software. A Waters symmetry, 4.6 x 150 mm, 5 A, C-18
column was used and coupled to a gamma detector. This system employed a Waters 1525
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Binary HPLC pump, Waters 2487 dual X absorbance detector, Waters In-Line degasser
and Breeze software (version 3.30). Flash chromatography was performed using a Merk
Silica gel 60 (230-400 mesh). Reactions were followed by TLC analysis, which were
carried out on EMD Silica Gel 60-F(254) plates. Analytical HPLC was performed using a
Grace Vydac Protein/Peptide RP-C18 column 4.6 x 250 mm, 5 pm or a Sunfire RP-C18
column 4.6 x 250 mm, 5 pm. Preparative HPLC was performed using a Grace Vydac
Peptide/Protein SP-C18 column 22.0 x 250 mm, 10 pm or a Sunfire SP-C18 column 22.0
x 250 mm, 10 pm. A gradient system was used: ACN + 0.1% TFA (solvent A) and water
+ 0.1% TFA (Solvent B). The absorbance was detected in the 200 nm to 500 nm
wavelength range.

4.4.2 General Procedure for Peptide Assembly
Fully protected resin bound peptides were synthesized manually according to the
general procedures in Fmoc solid phase peptide synthesis. Fmoc protected rink amide
MBHA resin (loading 0.56 or 0.47 meq/ g) was used as the solid support. N-Fmoc amino
acids with strong acid labile protecting groups for side chain functional groups, were used
in general, and Boc-Gly was used for the N-terminus. Fmoc-(Dpr), with the P-amine
protected through an allyloxycarbonyl (alloc) group, was used for residue-3. Fmoc
removal was achieved by adding 20% piperidine in DMF for 5 and 15 minutes, followed
by washes with DMF and DCM after each treatment. For each amino acid coupling, resin
was treated twice with 3 eq. of Fmoc or Boc amino acids, 3 eq. of 3[bis(dimethylamino)methyliumyl]-3//-benzotriazol-1-oxide
(HBTU) and

6

hexafluorophosphate

eq. of N,N-diisopropylehtylamine (DIPEA) in 2 mL of DMF for 30
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minutes to 2 hours. Couplings were followed by multpile washes with DMF, and CH2Cl2.
Using this general procedure, peptides were prepared on resin.

4.4.3 General Procedure for Selective Deprotection and Resin Cleavage
Selective deprotections were carried out using an orthogonal deprotection strategy
for Dpr3. The P-amine protected with allyloxycarbonyl (alloc) was selectively removed by
treating the resin with 0.35 eq. of tetrakis(triphenylphosphine)palladium (Pd(PPh3)4), and
20 eq. of phenylsilane (PhSiH3) in 2 mL of anhydous DCM. This treatment was repeated
twice, followed by successive washes with DMF and DCM. The Kaiser test was used to
monitor the presence or absence of a free amine. After further modifications to the Pamine of Dpr were complete, the peptide was deprotected and cleaved from the resin
using 95% TFA, 2.5% TIS, and 2.5% water for 3-6 hours. The resin was filtered and
rinsed with a small amount of TFA. Cold tert-butyl methyl ether (TBME) was added to
the filtrate to form a precipitate. Following the addition of TBME, the slurry was
centrifuged and decanted. The peptide was rinsed with TBME and collected again. The
solid was dissolved in water with the addition of acetonitrile (ACN) when needed, froze,
and lyophilized to obtain a crude peptide as a powder. Purification was carried out using
preparative HPLC, and the purity of the isolated product was determined by analytical
HPLC.

__

O

4.4.4 General Procedure for Fluorine Bearing Ghrelin(l-18), and [Tyr JGhrelin(l-8)
Analogues
Analogues 4.21, 4.22 and 4.24-4.27 were made on resin following a general
procedure similar to the synthesis of 2.16. Selective removal of alloc located off the P-
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amine of Dpr3 was deprotected according to the general procedure for selective
deprotections. Side Chains A (4-fluoro-1-naphthoic acid), B (fluorobenzoic acid), and C
(6 -fluoro-2 -naphthoic acid) were coupled to the peptide according to the general
procedure in peptide assembly. Successful couplings were washed and rinsed with DMF
and DCM. Following this, a final cleavage and deprotection was conducted according to
the general procedure to obtain the crude peptide.

4.4.5 [Dpr (fluorobenzoic acid)JGhrelin(l-18)-amide (4.21) and [Dpr3(4-fluoro-lnaphthoic acid)]Ghrelin(l-18)-amide (4.22)
Purification was performed by HPLC (gradient 30-80% solvent A in B) to obtain
4.21 and 4.22 with yields of 8.5% (18 mg), and 7% (16 mg) as white powders (ESI-MS
and purity reported in Table 4.5.)
4.4.6 [Dpr3(fluorobenzoic acid)][Tyrs]Ghrelin(l-8)-amide (4.24), [Dpr (4-fluoro-lnaphthoic acid)][Tyr [Ghrelin(l-8)-amide (4.25), IDpr3(6-fluoro-2-naphthoic
acid)][Tyr ]Glirelin(1-8)-amide (4.26) and [Tyr8]Ghrelin(l-8)-amide (4.27)
Purification was performed by HPLC (gradient 30-60% solvent A in B) to obtain
4.24,4.25, 4.26 and 4.27 with yields of 10%, 9.7%, 4% and 15% as white powders (ESIMS and purity reported in Table 4.7.
4.4.7 General Procedure for Protecting Carboxylic Acids
In a 250 mL three neck round bottom flask, 90 mL of ethanol was added to the
unprotected acid (1 eq.), while stirring under argon gas. Five eq. of 12M sulfuric acid
(H2 SO4 ) was added drop wise to the red solution while stirring in an ice bath. Following

the addition of sulfuric acid, the reaction was heated and refluxed between 85-90 °C for
24 hours. The reaction mixture was concentrated under reduced pressure. The resulting
red residue was extracted with dichloromethane and washed with a

0 .1

molar solution of
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sodium bicarbonate. The combined organic fractions were dried over MgS0 4 followed by
concentration in vacuo.

4.4.8 2-Ethyl 3-aminonaphthoate (4.32)
Green solid, 0.27 g (75%). Rf 0.31 (12% EtOAc/Hexanes); 'H-NMR (400 MHz, DMSOd6): 5 8.43 (s, 1H), 7.78 (dd, J = 8.2, 3.0 Hz, 1H), 7.52 (dd, J = 8.3, 3.0 Hz, 1H), 7.38
(ddd, J = 8.3, 6 .8 , 1.3 Hz, 1H), 7.12 (ddd, J = 8.1, 6 .8 , 1.2 Hz, 1H), 7.03 (s, 1H), 6.45 (s,
2H), 4.35 (q, J = 7.1 Hz, 2H), 1.36 (t, J = 7.1 Hz, 3H). I3C-NMR (101 MHz; DMSO-d6):
5 167.4, 147.1, 137.2, 132.8, 129.3, 128.9, 124.9, 124.9, 122.0, 114.2, 109.0, 60.7, 14.4.
HRMS (El) m/z calc for: C i3H i3N 0 2: 215.0952; found: 215.0950.

4.4.9

2-Ethyl 6-aminonaphthoate (4.39)

White solid, 0.15 g (89%). Rf 0.25 (5% EtOAc/Hexanes); 'H-NMR (400 MHz, DMSOd6): 5 8.43 (d, J = 1.3 Hz, 1H), 7.94-7.92 (m, 1H), 7.84 (dd, J = 8 .6 , 1.7 Hz, 1H), 7.7257.704 (m, 1H), 7.52 (br s, 2H), 7.17-7.16 (m, 2H), 4.33 (q, J = 7.1 H*. 2H), 1.34 (t, J =
7.1 Hz, 3H). HRMS (El) m/z calc for: C,3H 13N 0 2: 215.0952; found: 215.0946.

4.4.10 2-Ethyl 6-fluoronaphthoate (4.45)
White solid, 0.36 g (80%). Rf 0.50 (10% EtOAc/Hexanes); 'H-NMR (400 MHz, CDC13):
5 8.59-8.55 (m, 1H), 8.10-8.08 (m, 1H), 7.95 (dd, J = 9.01, 5.63 Hz, 1H), 7.81 (d, J =
8.65 Hz, 1H), 7.48 (dd, J = 9.63, 2.48 Hz, 1H), 7.34-7.7.29 (m, 1H), 4.45 (q, J = 7.13 Hz,
2H), 1.45 (t, J = 7.13 Hz, 3H). HRMS (El) m/z calc for: C,3H ,iF02: 218.0743; found:
218.0740.
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4.4.11 1-Ethyl 4-dimethylaminonaphthoate (4.52)
Yellow solid, 0.50 g, (70%). Rf 0.10 (10% EtOAc/Hexanes); 'H-NMR 400 MHz,
CDCI3): 5 8.95-8.91 (m, 1H), 8.37-8.35 (m, 1H), 8.21-8.19 (m, 1H), 7.89-7.87 (m, 1H),
7.81-7.71 (m, 2H), 4.46 (q, 7= 7.1 Hz, 2H), 3.52 (s, 6 H), 1.47 (t, 7=7.1 Hz, 3H).

4.4.12 General Procedure for Reductive Amination o f Aromatic Amines
A modified literature procedure was followed

1 or

. To a solution containing an aromatic

amine (1 eq.) in 20 mL of methanol, was added sodium cyanoborohydride (10 eq.) and
formaldehyde (37% in water, 20 eq.). To this solution, 99.8% acetic acid was added drop
wise until the solution reached a pH of 3-5. The mixture was stirred at room temperature
and monitored by TLC until completion. The reaction mixture was concentrated under
reduced pressure. The resulting yellow residue was extracted with dichloromethane and
washed with a 0.1 molar solution of sodium bicarbonate. The combined organic fractions
were dried over MgSC>4 followed by concentration in vacuo.

4.4.13 3-Dimethylamino-2-naphthoic acid (4.31)
Green solid, 0.25 g (50%). Rf 0.2 (10% MeOH/DCM) 'H-NMR (400 MHz, CDC13):

8

8.549 (d, J = 0.33 Hz 1H), 7.998 (dd, J = 8 .6 8 , 1.45 Hz, 1H), 7.876-7.853 (m, 1H), 7.7137.692 (m, 1H), 7.04-6.94 (br s, 1H), 3.131 (s, 6 H).

4.4.14 2-Ethyl 3-dimethylaminonaphthoate (4.33)
Yellow solid, 0.27 g (75%). Rf0.18 (5% EtOAc/Hexanes); 'H-NMR (400 MHz, DMSOd6 ): 5 8.48 (m, 1H), 8.09-8.07 (m, 1H), 7.95-7.70 (m, 1H), 7.65-7.63 (m, 1H), 7.56 (s,
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1H), 7.50-7.47 (m, 1H), 4.41 (q, J = 7.1 Hz, 2H), 3.15 (s, 6 H), 1.39 (t, J = 7.1 Hz, 3H).
HRMS (El) m/z calc for: C i5H,7N 0 2: 243.1259; found: 243.1137.

4.4.15 6-Dimethylamino-2-naphthoic acid (4.37)
Orange solid, 0.73 g (64%). Rf 0.5 (10% MeOH/DCM); 'H-NMR (400 MHz, CDC13): 5
8.55 (d, J = 0.3 Hz, 1H), 8.00 (dd, J = 8.7, 1.4 Hz, 1H), 7.84 (m, J = 9.1 Hz, 1H), 7.68 (m,
J = 8.7 Hz, 1H), 7.25-7.20 (m, 1H), 7.04-6.94 (m, 1H), 3.13 (s, 6 H). HRMS (El) m/z calc
for: CnHnNOz: 215.0946; found: 215.0945.

4.4.16 2-Ethyl 6-dimethylaminonaphthoate (4.40)
Yellow solid, 0.27 g (75 %). Rf 0.20 (10% EtOAc/Hexanes); 'H-NMR (400 MHz,
CDC13): 5 8.47 ( d, J = 1.3 Hz, 1H), 7.97 (dd, J = 8 .6 , 1.7 Hz, 1H),7.79 (d, J = 9.1 Hz,
1H), 7.64 (d, J = 8.7 Hz, 1H), 7.15 (dd, J = 9.1, 2.5 Hz, 1H), 6 . 8 8 (m, 1H), 4.42 (q, J = 7.1
Hz, 2H), 3.07 (s, 6 H), 1.44 (t, J = 7.1 Hz, 3H). ,3C-NMR (101 MHz; CDC13): 5 167.4,
150.1, 137.6, 131.0, 130.5, 126.11, 125.99, 125.5, 123.6, 116.4, 105.6, 60.8, 40.6, 14.7.
HRMS (El) m/z calc for: C,5H 17N 0 2: 243.1259; found: 243.12560.

4.4.17 2-Ethyl 3-methylammonapthoate (4.34)
Yellow Solid, 0.14 g (50 %). Rf 0.5 (15% EtOAc/Hexanes); 'H-NMR (400 MHz,CDC13):
5 8.54 (s, 1H), 7.74 (m, 1H), 7.65 (m, 1H), 7.45 (ddd, J = 7.6, 1.1, 1.1 Hz, 1H), 7.22 (ddd,
J = 7.5, 0.8, 0.8 Hz, 1H), 7.03 (s, 1H), 4.41 (q, J = 7.1 Hz, 2H), 3.01 (s, 3H), 1.45 (t, J =
7.2 Hz, 3H).
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4.4.18 General Procedure for Forming a Quaternary Ammonium Salt
To a 25 mL round bottom flask placed in an ice bath, the desired tertiary aromatic amine
(1 eq.) was dissolved in 5 mL of dry dichloromethane and cooled to 0 °C using an ice
bath. While stirring under argon gas, methyl trifluoromethanesulfonate (4 eq.) was added
drop wise to the reaction mixture. The mixture was stirred for 30 minutes at 0 °C. At this
time a white precipitate formed and the solution was allowed to stir for an additional 30
minutes. The white precipitate was filtered off, and dried under vacuo.

4.4.19 6-(N, N, N-trimethylammonium trifluorometliansulfonyl)-2 naphthoic acid
(4.38)
White solid, 0.18 g (50%). 'H-NMR (400 MHz, DMSO-d6): 5 8.73 (m, 1H), 8.62-8.60
(m, 1H), 8.45-8.43 (m, 1H), 8.38-8.37 (m, 1H), 8.24-8.20 (m, 2H), 3.72 (s, 9H). ESI-MS
calc for: C i4H,6N02: 230.3; found [M+H]+: 231.0.
4.4.20 2-ethyl 6-(N, N, N-trimethylammonium trifluoromeihansulfonylj-naphthoate
(4.41)
White solid, 0.18 g (56%). 'H-NMR (400 MHz, DMSO-d6): 5 8.75 (m, 1H), 8.63 (m,
1H), 8.45 (m, 1H), 8.26-8.21 (m, 2H), 8.15 (m, 1H), 4.40 (q, J = 7.1 Hz, 2H), 3.74 (s,
10H), 1.38 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz; dmso): 5 14.40, 56.54, 56.58, 61.43,
119.35, 119.57, 122.52, 125.73, 126.80, 129.45, 129.75, 130.19, 131.89, 132.13, 134.50,
146.33, 165.67. ESI m/z calc for: C 16H20NO2 : 258.15; found [M+H]+: 258.20.

4.4.21 4-(N,N,N-trimethylammonium triJliioromethansulfonyl)-l-naphthoic acid (4.49)
White solid, 0.27 g (70%). 'H-NMR (400 MHz, DMSO-d6): 5 13.84 (bs, 1H), 8.87-8.85
(m, 1H), 8.73-8.71 (m, 1H), 8.20 (d, J = 8.5 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.88-7.85
(m, 2H), 3.95 (s, 9H). ESI m/z calc for: C hH]6N02+: 230.11; found: 230.10.
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4.4.22 4-dimethylamino-l-napthoic acid (4.48)
In a 100 mL three necked round bottom flask, l,4-diazabicyclo[2.2.2]octane (1.12 g, 0.01
mol) was dissolved in 15 mL dry chloroform. While stirring at 0 °C, oxalyl chloride (1.71
g, 0.01 mol) was added dropwise to the reaction mixture. Upon the formation of a yellow
precipitate, dimethyl naphthalene 4.47 dissolved in 30 mL dry chloroform, was added
dropwise using an addition funnel over the course of one hour. The reaction mixture was
refluxed at 75 °C overnight and monitored by thin layer chromatography. The reaction
mixture was concentrated under reduced pressure. The resulting orange residue was
extracted with chloroform and acidified water at pH 3-4. The combined organic fractions
were dried over MgSCfi followed by concentration in vacuo yielding 0.71 g (33%) of an
orange precipitate. Rf 0.05 (100% CHC13); 'H-NMR (400 MHz, DMSO-d6): 5 12.70 (s,
1H), 9.01-8.99 (m, 1H), 8.18-8.11 (m, 1H), 7.61-7.51 (m, 3H), 7.08-7.06 (m, lH),2.88(s,
6H). HRMS (El) m/z calc for: C i3H i3N 0 2: 215.0946; found: 215.0943.

4.4.23 4-dimethylamino-l-naphthaldehyde (4.50)
N, N-Dimethyl-l-naphthylamine (1.6 mL, 10 mmol) and trimethyl orthoformate (1.62
mL, 15 mmol) were stirred at 0 °C in anhydrous DCM (40 mL) under nitrogen. Titanium
tetrachloride (4.4 mL TiCfi, 20 mmol) in 20 mL anhydrous DCM, was added dropwise
over 4 hours to the stirring solution. The reaction was then warmed to room temperature
and stirred overnight. Saturated K2C 0 3 solution (30 mL) was added to the reaction and
stirred for 1 hour. The reaction mixture was filtered through a Buchner funnel. The
resulting red solution was concentrated in vacuo and then extracted with DCM. The
combined organic fractions were dried over MgSC>4 followed by concentration in vacuo
yielding 1.3 g (80%) of a red precipitate. Rf 0.10 (5% EtOAc/Hexanes); 'H-NMR (400
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MHz, CDCI3): 5 10.17 (s, 1H), 9.37-9.35 (m, 1H), 8.19-8.17 (m, 1H), 7.83 (d, J = 7.93
Hz, 1H), 7.67-7.62 (m, 1H), 7.55-7.52 (m, 1H), 7.03 (d, J = 7.93 Hz, 1H), 3.03 (s, 6 H).
HRMS (El) m/z calc for: C 13H 13NO: 199.0997; found: 199.1000.

4.4.24 4-dimethyl-1-naphthoic acid (4.51)
In a 100 mL double neck round bottom flask, 4-dimethylamino-l-naphthaldehyde 4.50 (1
eq., 0.82 mmol) was dissolved in a 4:1 solution of acetone/water. Potassium
Permanganate (KMn04, 5 eq., 4.1 mmol) was dissolved in

8

mL acetone/water (4:1) and

then added dropwise to the stirring solution over 30 minutes. The reaction was then
refluxed at 60 °C and monitored by thin layer chromatography. The resulting red solution
was concentrated in vacuo and then filtered through a Buchner funnel. The combined
aqueous solution was acidified with

6

M HC1 and then extracted in DCM. The combined

organic fractions were dried over MgS0 4 followed by concentration in vacuo yielding
0.1 Og (57%) of a yellow precipitate. Rf 0.20 (7.5% MeOH/DCM); 'H-NMR (400 MHz,
CDCI 3 ): 5 9.14-9.12 (m, 1H), 8.31 (d, J = 8.11 Hz 1H), 8.20 (dd, J = 8.47, 0.75 Hz 1H),

7.58-7.48(m, 2H), 6.98 (d, J = 8.15 Hz 1H), 2.96 (s, 6 H).

to

4.4.25 F-18 radiolabelling procedure 2-Ethyl 6- fluoronaphthoate (4.46)
1
Nucleophilic fluorine-18 was prepared by passing a solution of F/H2O (0.5 mL) through
o

an anion exchange column and eluting with a 2 mL solution of K^CCVKryptofix 2.2.2.
Azeotropic removal of water was achieved by adding 500 pL of anhydrous ACN and
heating (55 °C) the solution while under nitrogen. A second portion of 500 pL of
anhydrous ACN was added followed by heating (55 °C) under nitrogen. The quaternary
ammonium salt 4.41 dissolved in 1 mL of anhydrous DMSO was then added to the dried
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18
K F-Kryptofïx 2.2.2 complex. The reaction mixture was stirred and heated to 160 °C for
15 minutes. Product 4.46 was then analyzed using RP-HPLC coupled to a gamma
detector and compared to the UV trace of non-radioactive standard 4.45.
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C hapter Five: C onclusions
In 2008, it was estimated that 12.7 million new cases and 7.6 million deaths
occurred worldwide from cancer related diseases137. The World Health Organization has
recently estimated deaths from cancer to continue to rise to 11 million by 2030, even
though it was reported that 30% of cancers could be avoided by reducing high risk factors
such as tobacco use, physical inactivity and urban air137. More importantly, new
approaches in diagnosing and treating cancer at its initial stages may result in a decrease
in cancer related deaths.
The development of molecular imaging agents serves as a non-invasive approach
to diagnosing cancer related diseases. Molecular imaging can be defined as the
“visualization representation, characterization and quantification of a biological process
occurring at the cellular and sub cellular levels” . Today, much of the existing research
focuses on the design, synthesis and characterization of new imaging agents targeting a
variety of cancers. In one approach, an imaging probe is designed and synthesized in
order to target a highly overexpressed cancer-specific receptor. In general, this agent
consists of two parts: (a) a biomolecular vehicle and (b) a signalling source. In addition to
selecting the appropriate targeting vehicle and receptor-ligand, various modifications
must be made to ensure the probe displays high specificity and affinity towards the
receptor of interest. Following this step, the synthesized probe is then evaluated in a
number of in vitro and in vivo assays, to confirm the effectiveness in targeting a cancerspecific receptor.
In this thesis, a molecular imaging agent targeting a highly overexpressed cancerspecific receptor was designed and synthesized. Ghrelin is a 28-amino acid peptide
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hormone and is the endogenous ligand for the growth hormone secretagogue receptor
(GHSR). Our initial design feature used truncated ghrelin analogues as the biomolecular
vehicle, based on evidence suggesting the GHSR was highly overexpressed in a number
of tumour models. As an initial study, the objective was to design a non-radioactive
imaging probe that could target the GHSR with high affinity and specificity. It was
evident from past structure activity relationship studies, that ghrelin’s unique Ser-3
lipophilic side chain, N-terminal amine and Phe4 residue were critical for receptor
recognition. Thus, the location of the signalling source was positioned towards the Cterminus, off a pendent lysine side chain to avoid interference with ghrelin’s N-terminal
binding region. Additional modifications by replacing both Ser3 with Dpr3 and the Cterminal carboxylic acid with an amide moiety ensured additional in vivo stability.
The design and synthesis of fluorescein-ghrelin 2.21 was accomplished by using
an orthogonal protecting group strategy. This ensured the selective addition of both the
unique octanoylated side chain and fluorescein isothiocyanate at residues 3 and 19. To
our knowledge, this is the first reported design and synthesis of a ghrelin optical imaging
agent. Fluorescein-ghrelin 2.21 displayed a 9.5 nM IC50 value, similar to that of native
ghrelin’s 8.1 nM affinity for the GHSR. In addition, the half-life of fluorescein-ghrelin
2.21 incubated in rat serum was 33 minutes, which was similar to that of native ghrelin’s
27 minute half-life. Thus, the C-terminal addition of a bulky substituent confirms the use
of 2.21 to be stable for future in vivo imaging studies. Furthermore, 2.21 displayed high
uptake in both PC3 and LNCaP cells as well as ex vivo prostate cancer tissue.
Importantly, preferential uptake was found in prostatic intraepithelial neoplasia (PIN) and
prostate cancer (PCa), as compared to normal prostate and benign prostatic hyperplasia
(BPH). In an additional study, we looked at GHSR expression in a murine model by
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western blot analysis and found the GHSR-la was overexpressed in the heart and brain.
To confirm the expression of the GHSR-la present within the heart, our fluoresceinghrelin 2.21 was incubated in ex vivo murine heart tissue. Using confocal microscopy,
2.21 displayed high uptake noted by the bright fluorescence observed within heart tissue.
These results suggest an additional use of our fluorescein-ghrelin 2.21 in monitoring heart
disease in patients with cardiomyopathy. Both of these studies validated our probes
effectiveness in both in vitro and ex vivo imaging studies. More importantly, the design
and synthesis of 2.21 allowed us to modify native ghrelin while still maintain potent
receptor recognition to the GHSR-la. These modifications supported the development of
positron emission tomography (PET) agents.
The next step in developing an imaging agent was to create a radioactive analogue
for PET nuclear imaging. Two different approaches were used to incorporate either
gallium-68 or fluorine-18 into the backbone of modified ghrelin.
In the first approach (chapter three), tris-t-butyl-DOTA, a radio-metal chelate, was
incorporated into a pendent lysine side chain on the C-terminus of a modified 18-mer
ghrelin analogue. A similar orthogonal protecting group strategy as for the synthesis of
2.21 allowed for addition of tris-t-butyl-DOTA. Binding affinities of 2.29 nM and 9.1 nM
was observed for both unlabelled 3.6 and gallium labelled 3.7 modified ghrelin,
demonstrating the ability to incorporate a radio-metal chelate while still maintaining
receptor recognition. The development of a radiolabelling strategy yielded the 68Ga
modified ghrelin 3.8 in a 75% radiochemical yield. To our knowledge, the design and
synthesis of a gallium-68 ghrelin analogue used for PET nuclear imaging hasn’t been
achieved up until now. The effectiveness of 3.8 will be evaluated by imaging a small
animal with localized prostate tumours using PET nuclear imaging.
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In the second approach (chapter four), non-radioactive fluorine labelled ghrelin
analogues were synthesized based on previous results suggesting other bulky,
hydrophobic groups could replace ghrelin’s unique lipophilic side chain. Initially 18-mer
modified ghrelin analogues were synthesized to incorporate either fluorobenzoic acid
4.21 or fluoronaphthoic acid 4.22 into the Dpr3 side chain. Binding assays confirmed the
non-radioactive fluorine labelled ghrelin(l-18)-amide analogues had better binding
affinity then native ghrelin. Interestingly, incorporating the bulkier naphthyl substituent as
in 4.22 provided enhanced binding affinity over benzene 4.21. This supported the
additional design and synthesis of analogues containing naphthyl substituents.
The design and synthesis of lower molecular weight nonradioactive fluorine
compounds helped determined the minimal binding sequence capable of binding to the
GHSR. Truncated ghrelin(l-8)-amide analogues were synthesized with the addition of
Tyr-8 replacing Glu-8, based on previous structure-activity relationships. Modified
ghrelin with the less bulky benzene side chain as in 4.24, reported a 440 nM binding
affinity. However, when replacing the native octanoylated side chain with a naphthyl
aromatic ring as in 4.25, the binding affinity drastically improved to 9.9 nM.
Based on the low nM binding affinities, a prosthetic group approach for
incorporating radioactive fluorine-18 into the low molecular weight [Tyr8]ghrelin(l-8)amide analogues was designed. A fluorine-18 labelled naphthalene ring was synthesized
using nucleophilic aromatic substitution. To our knowledge this is the first synthesis of a
radiolabelled naphthalene ring used as a prosthetic group. Additional methodologies for
incorporating this prosthetic group into the Dpr3 side chain needs to be evaluated prior to
using this agent for PET nuclear imaging.
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The development of novel ghrelin-based imaging agents has been discussed for
their use in PET nuclear imaging. This project has progressed through the design,
synthesis and in vitro evaluation of truncated ghrelin analogues, resulting in fluorine and
gallium labelled peptides with high receptor potency. The lead analogues are ready to be
evaluated for in vivo stability and specificity. Numerous optimization studies will be
needed in order to carry this probe into a pre-clinical study. Nonetheless, the future of
ghrelin as a molecular imaging probe for diagnosing early stage prostate cancer looks
very promising.
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A ppendix A: ’H -N M R , H PL C and M S-ESI o f selected com pounds

H P L C a n d M S -E S I spectra o f
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H P L C a n d M S -E S I spectra o f [D p r3(O ctanoic acid)] g h re lin (l-1 8 )-a m id e (2.22)
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H P L C a n d M S -E S I spectra o f
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H P L C a n d M S -E S I spectra o f
[D pr(octan oyl)3, L y s(G a 69/70-D O T A )l9J g h re lin (l-1 9 )-a m id e (3.7)
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H P L C a n d M S -E S I spectra o f
¡D pr (flu oroben zoic a cid )]G h relin (l-1 8 )-a m id e (4.21)
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HPLC and MS-ESI spectra o f ¡Dpr3(fluorobenzoic acid)][Tyr8]Ghrelin(l-8)-amide
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H P L C a n d M S -E S I spectra o f

[Dpr3(4-fluoro-1-naphthoic acid)][Tyr8]Gh relin (1-8)-amide (4.25)

MMQC-02-138-5 30to80 10mm-sunfire

2 Diode Array
Range 5 163e+1

Tm e
15.00

"m T i 1 1 1 1 1 1 M i l I

13.00

M M Q C -0 2-13 8-5_ 30 to8 0 _ 10 m in -sunfire 6 5 6 (6.609)

14.00

126
H P L C a n d M S -E S I spectra o f
[D p r3(6-flu oro-2-n aph th oic acid)]IT yr8IG h reIin (l-8 )-a m id e (4.26)
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H P L C a n d M S -E S I spectra o f

/ D pr3(O ctanoic acid)! [ T yrJ G h relin (1-8)-am ide (4.27)
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'H -N M R spectrum o f
3-dim eth ylam in o-2-n aph th oic a cid (4.31) in CDCI3
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1H -N M R spectru m o f
2 -E th yl 3-am in on aph th oate (4.32) in DMSO-tU
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'H -N M R spectrum o f
2-E th yl 3-dim eth yiam in on aph th oate (4.33) in DMSO-dé
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'H -N M R spectrum o f
2-E th yl 6-am in on aph th oate (4.39) DMSQ-dé

132
'H -N M R spectrum o f
2 -E th yl 6-dim eth ylam in on aph th oate (4.40) in CDCI3
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'H -N M R spectrum o f

2-Ethyl 6-(N, N, N-trimethylammonium)-naphthoate (4.41)
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1.1.1 1H-NMR spectrum of
2-Ethyl 6-fluoronaphthoate (4.45)
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'H -N M R spectru m o f
4-dim eth yla m in o -l-n a p h th yIa ld eh yd e (4.51) in CDCI3
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'H -N M R spectrum o f

4-dimethylamino-l-naphthoic acid (4.51) in CDCI3
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'H -N M R spectrum o f
l-E th yl-4-dim eth yla m in o -n a p h th o a te (4.52) in CDCI3
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